Shareholder Alert: The Ademi Firm investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders News provided by Ademi LLP Mar 30, 2026, 12:25 ET Share this article Share to X Share this article Share to X MILWAUKEE , March 30, 2026 /PRNewswire/ -- Ademi LLP is investigating Kezar (NASDAQ: KZR ) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Aurinia. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Kezar stockholders will receive $6.955 in cash per share plus one contingent value right (CVR). The CVR provides rights to potential payments from the clinical development of zetomipzomib, proceeds from Kezar's collaboration with Everest Medicines and sale of its Sec61-based program to Enodia Therapeutics, and 100% of Kezar's closing net cash exceeding $50 million, net of certain expenses. Kezar insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Kezar by imposing a significant penalty if Kezar accepts a competing bid. We are investigating the conduct of the Kezar board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts Ademi LLP Guri Ademi Toll Free: (866) 264-3995 Fax: (414) 482-8001 SOURCE Ademi LLP 21 % more press release views with  Request a Demo × Modal title

DRVN Investors Have Opportunity to Lead Driven Brands Holdings Inc. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Apr 04, 2026, 12:15 ET Share this article Share to X Share this article Share to X NEW YORK , April 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Driven Brands Holdings Inc. (NASDAQ: DRVN ) between May 9, 2023 and February 24, 2026, both dates inclusive (the "Class Period"), of the important May 8, 2026 lead plaintiff deadline. So What: If you purchased Driven Brands common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Driven Brands class action, go to https://rosenlegal.com/submit-form/?case_id=18662 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose Driven Brands' financial condition and the effectiveness of its internal controls over financial reporting through a series of inaccurate financial reports filed with the Securities and Exchange Commission ("SEC") from May 9, 2023, to November 5, 2025. Among many other errors, Driven Brands' balance sheets contained an unreconciled cash balance originating in 2023 which resulted in revenue and cash being overstated in 2023 and 2024, and operating expenses being understated over the same period. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Driven Brands class action, go to https://rosenlegal.com/submit-form/?case_id=18662 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Apr 04, 2026, 01:16 ET Share this article Share to X Share this article Share to X NEW YORK , April 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA ) between May 20, 2024 and January 9, 2026, inclusive (the "Class Period"), of the important May 22, 2026 lead plaintiff deadline. So what: If you purchased Atara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Atara class action, go to https://rosenlegal.com/submit-form/?case_id=57137 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 22, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) certain manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the U.S. Food and Drug Administration ("FDA") would approve the tabelecleucel Biologics License Application ("BLA"); (2) accordingly, tabelecleucel's regulatory prospects were overstated; (3) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical trials; (4) all the foregoing was likely to have a significant negative impact on Atara's business and financial condition; and (5) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Atara class action, go to https://rosenlegal.com/submit-form/?case_id=57137 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit News provided by Law Offices of Howard G. Smith Apr 03, 2026, 15:24 ET Share this article Share to X Share this article Share to X BENSALEM, Pa. , April 3, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX ). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BOSTON SCIENTIFIC CORPORATION (BSX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MAY 4, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected] , by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com . What Is The Lawsuit About? The complaint filed alleges that, between July 23, 2025 and February 3, 2026, Defendants failed to disclose to investors that: (1) Boston Scientific's U.S. EP segment's growth rate was unsustainable and was approaching an earlier tipping point than the market was anticipating; (2) the Company was experiencing new competition entrants that were sapping Boston Scientific's U.S. Electrophysiology market share and thus limiting the Company's growth potential; (3) as a result, Defendants' repeated statements of confidence in the U.S. EP division's growth trajectory, including repeatedly elevated full-year guidance metrics, were materially misleading; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact: Howard G. Smith, Esq., Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Call us at: (215) 638-4847 Email us at: [email protected] , Visit our website at: www.howardsmithlaw.com . To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact Us: Law Offices of Howard G. Smith Howard G. Smith, Esquire 215-638-4847 [email protected] www.howardsmithlaw.com SOURCE Law Offices of Howard G. Smith 21 % more press release views with  Request a Demo × Modal title

SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Apr 05, 2026, 19:18 ET Share this article Share to X Share this article Share to X NEW YORK , April 5, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO ) between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline. So what: If you purchased Soleno common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Soleno class action, go to https://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases . Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Soleno Phase 3 clinical trial program for diazoxide choline extended-release tablets ("DCCR") had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (2) as a result, the administration of DCCR to treat hyperphagia in individuals with Prader-Willi syndrome ("PWS") posed materially greater safety risks than disclosed by Soleno or its executives; and (3) as a result, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Soleno class action, go to https://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

Vital Farms, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VITL News provided by DJS Law Group LLP Apr 03, 2026, 01:49 ET Share this article Share to X Share this article Share to X LOS ANGELES , April 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Vital Farms, Inc. ("Vital Farms" or "the Company") (NASDAQ: VITL ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of VITL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: May 8, 2025 to February 26, 2026 DEADLINE: May 26, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Vital Farms' project to change its enterprise resource planning ("ERP") system caused delays, despite the fact it had downplayed the risk of delays occurring. These ERP delays hindered the Company's performance. Based on these facts, Vital Farm's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email: [email protected] SOURCE DJS Law Group LLP 21 % more press release views with  Request a Demo × Modal title

SMR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds NuScale (SMR) Investors of Securities Class Action Deadline on April 20, 2026 News provided by Faruqi & Faruqi, LLP Apr 10, 2026, 11:45 ET Share this article Share to X Share this article Share to X Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In NuScale To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in NuScale between May 13, 2025 and November 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . [You may also click here for additional information] NEW YORK , April 10, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against NuScale Power Corporation ("NuScale" or the "Company") (NYSE: SMR ) and reminds investors of the April 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com . As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) ENTRA1 had never built, financed, or operated any significant projects – let alone projects in the highly technical and complicated field of nuclear power generation – during its entire operating history; (ii) NuScale had entrusted its commercialization, distribution, and deployment of its NPMs and hundreds of millions of dollars of NuScale capital to an entity that lacked any significant prior experience owning, financing, or operating nuclear energy generation facilities; (iii) the purported experience and qualifications attributed to ENTRA1 by defendants during the Class Period in fact referred to the purported experience and qualifications of the principals of the Habboush Group, a distinct entity without significant experience in the field of nuclear power generation; and (iv) as a result, NuScale's commercialization strategy was exposed to material, undisclosed risks of failure, delays, regulatory challenges, or other negative setbacks. On November 6, 2025, NuScale surprised investors by revealing that the Company's general and administrative expenses had ballooned more than 3,000% to $519 million during its third fiscal quarter, up from $17 million in the prior year period, due largely to NuScale's payment of $495 million to ENTRA1 for its TVA agreement. As a result, NuScale's quarterly net loss skyrocketed to $532 million, up from $46 million in the prior year period. On this news, the price of NuScale Class A shares declined more than 12% over a two-day trading period, from approximately $32 per share on November 6, 2025 to approximately $28 per share on November 10, 2025. The price of NuScale Class A stock continued to fall in subsequent days, dropping to a low of just $17 per share by November 21, 2025 – more than 70% below the class period high of more than $57 per share. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding NuScale's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the NuScale class action, go to www.faruqilaw.com/SMR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . us for updates on LinkedIn , on X , or on Facebook . Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. SOURCE Faruqi & Faruqi, LLP As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) ENTRA1 had never built, financed, or operated any significant projects – let alone projects in the highly technical and complicated field of nuclear power generation – during its entire operating history; (ii) NuScale had entrusted its commercialization, distribution, and deployment of its NPMs and hundreds of millions of dollars of NuScale capital to an entity that lacked any significant prior experience owning, financing, or operating nuclear energy generation facilities; (iii) the purported experience and qualifications attributed to ENTRA1 by defendants during the Class Period in fact referred to the purported experience and qualifications of the principals of the Habboush Group, a distinct entity without significant experience in the field of nuclear power generation; and (iv) as a result, NuScale's commercialization strategy was exposed to material, undisclosed risks of failure, delays, regulatory challenges, or other negative setbacks. On November 6, 2025, NuScale surprised investors by revealing that the Company's general and administrative expenses had ballooned more than 3,000% to $519 million during its third fiscal quarter, up from $17 million in the prior year period, due largely to NuScale's payment of $495 million to ENTRA1 for its TVA agreement. As a result, NuScale's quarterly net loss skyrocketed to $532 million, up from $46 million in the prior year period. On this news, the price of NuScale Class A shares declined more than 12% over a two-day trading period, from approximately $32 per share on November 6, 2025 to approximately $28 per share on November 10, 2025. The price of NuScale Class A stock continued to fall in subsequent days, dropping to a low of just $17 per share by November 21, 2025 – more than 70% below the class period high of more than $57 per share. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding NuScale's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the NuScale class action, go to www.faruqilaw.com/SMR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . us for updates on LinkedIn , on X , or on Facebook . Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. SOURCE Faruqi & Faruqi, LLP --> 21 % more press release views with  Request a Demo × Modal title

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC News provided by Kahn Swick & Foti, LLC Apr 10, 2026, 22:12 ET Share this article Share to X Share this article Share to X NEW YORK and NEW ORLEANS , April 10, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) ("Corcept" or the "Company"), if they purchased or otherwise acquired the Company's shares between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California. Continue Reading Kahn Swick & Foti Speed Speed --> What You May Do If you purchased shares of Corcept and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( [email protected] ), or visit https://www.ksfcounsel.com/cases/nasdaqcm-cort/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 21, 2026 . About the Lawsuit Corcept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The complaint alleges that, during the Class Period, the Company represented to investors that there was a high likelihood that one of its lead new product candidates, relacorilant, would receive approval from the U.S. Food and Drug Administration ("FDA") after the Company's New Drug Application ("NDA") submission. However, on December 31, 2025, the Company disclosed that the FDA had issued a Complete Response Letter ("CRL") regarding the NDA for relacorilant and that it had "concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness." On this news, the price of Corcept's shares plummeted by $35.40 per share, or 50.4%, from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025. The case is Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525. About Kahn Swick & Foti , LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit www.ksfcounsel.com . Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn SOURCE Kahn Swick & Foti, LLC 21 % more press release views with  Request a Demo × Modal title

TCPC Deadline: TCPC Investors with Losses in Excess of $100K Have Opportunity to Lead BlackRock TCP Capital Corp. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Apr 04, 2026, 18:51 ET Share this article Share to X Share this article Share to X NEW YORK , April 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BlackRock TCP Capital Corp. (NASDAQ: TCPC ) between November 6, 2024 and January 23, 2026, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. So what: If you purchased BlackRock TCP securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the BlackRock TCP class action, go to https://rosenlegal.com/submit-form/?case_id=52921 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about BlackRock TCP's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) BlackRock TCP's investments were not being timely and/or appropriately valued; (2) BlackRock TCP's efforts at portfolio restructuring were not effectively resolving challenged credits or improving the quality of the portfolio; (3) as a result, BlackRock TCP's unrealized losses were understated; (4) as a result, BlackRock TCP's NAV was overstated; and (5) as a result of the foregoing, defendants' positive statements about BlackRock TCP's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the BlackRock TCP class action, go to https://rosenlegal.com/submit-form/?case_id=52921 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

LAKE Investors Have Opportunity to Lead Lakeland Industries, Inc. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Apr 06, 2026, 21:38 ET Share this article Share to X Share this article Share to X NEW YORK , April 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lakeland Industries, Inc. (NASDAQ: LAKE ) between December 1, 2023 and December 9, 2025, inclusive (the "Class Period"), of the April 24, 2026 lead plaintiff deadline. So What: If you purchased Lakeland securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Lakeland class action, go to https://rosenlegal.com/submit-form/?case_id=50020 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 24, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Lakeland was experiencing significant, sustained issues with its Pacific Helmets and Jolly businesses, including, inter alia, shipping-related delays, production issues, and slower than expected rollout of new products; (2) accordingly, defendants overstated the anticipated and actual positive impact of these businesses on Lakeland's financial results, as well as the overall strength and quality of Pacific Helmets' and Jolly's respective operations; (3) Lakeland's business and financial results were significantly deteriorating because of, inter alia, tariff-related headwinds and timing, certification delays, and material flow issues in its acquired businesses; (4) accordingly, defendants overstated the strength of their tariff mitigation measures and "small, strategic, and quick" ("SSQ") M&A strategy; (5) as a result of all the foregoing issues, defendants' financial guidance was unreliable; and (6) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Lakeland class action, go to https://rosenlegal.com/submit-form/?case_id=50020 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

PSIX Investors Have Opportunity to Lead Power Solutions International, Inc. Securities Fraud Lawsuit with the Schall Law Firm News provided by The Schall Law Firm Apr 01, 2026, 03:08 ET Share this article Share to X Share this article Share to X LOS ANGELES , April 1, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Power Solutions International, Inc. ("Power Solutions" or "the Company") (NASDAQ: PSIX ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2025 and March 2, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before May 19, 2026. If you are a shareholder who suffered a loss, click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com , or by email at [email protected] . The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Power Solutions misled investors about its ability to win business in the data center market. The Company downplayed the impact of its manufacturing enhacements, including costs and "inefficiencies." Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Power Solutions, investors suffered damages. Join the case to recover your losses The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq., www.schallfirm.com Office: 310-301-3335 [email protected] SOURCE The Schall Law Firm 21 % more press release views with  Request a Demo × Modal title

SMCI Investors Have Opportunity to Lead Super Micro Computer, Inc. Securities Fraud Lawsuit with the Schall Law Firm News provided by The Schall Law Firm Apr 03, 2026, 01:12 ET Share this article Share to X Share this article Share to X LOS ANGELES , April 3, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Super Micro Computer, Inc. ("Super Micro" or "the Company") (NASDAQ: SMCI ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 30, 2024 and March 19, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before May 26, 2026. If you are a shareholder who suffered a loss, click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com , or by email at [email protected] . The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Super Micro derived significant revenue from sales of servers to China that violated U.S. export control laws. The Company failed to maintain appropriate controls to ensure compliance with export laws. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Super Micro, investors suffered damages. Join the case to recover your losses The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq., www.schallfirm.com Office: 310-301-3335 [email protected] SOURCE The Schall Law Firm 21 % more press release views with  Request a Demo × Modal title

Rosen Law Firm Encourages zSpace Inc. Investors to Inquire About Securities Class Action Investigation - ZSPC News provided by THE ROSEN LAW FIRM, P. A. Apr 04, 2026, 15:03 ET Share this article Share to X Share this article Share to X NEW YORK , April 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of zSpace Inc. (NASDAQ: ZSPC ) resulting from allegations that zSpace may have issued materially misleading business information to the investing public. So What: If you purchased zSpace securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=58151 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. What is this about: Rosen Law Firm is investigating potential civil securities claims. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit News provided by Robbins Geller Rudman & Dowd LLP Apr 03, 2026, 23:14 ET Share this article Share to X Share this article Share to X SAN DIEGO , April 3, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX ) publicly traded securities between January 19, 2026 and March 24, 2026, inclusive (the "Class Period"), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit. Captioned Douglas v. ImmunityBio, Inc. , No. 26-cv-03261 (C.D. Cal.), the ImmunityBio class action lawsuit charges ImmunityBio as well as ImmunityBio's Executive Chairman with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the ImmunityBio class action lawsuit, please provide your information here: https://www.rgrdlaw.com/cases-immunitybio-class-action-lawsuit-ibrx.html You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected] . CASE ALLEGATIONS : ImmunityBio is a biotechnology company that focuses on innovating, developing, and commercializing next-generation immunotherapies. According to the complaint, ImmunityBio's lead biologics product is Anktiva. The ImmunityBio class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) representations that "Anktiva will allow all NMIBC patients treated with Anktiva to be cancer-free for the long term, when this has not been demonstrated"; (ii) the claim that Anktiva is a cancer vaccine was false; and (iii) ImmunityBio's Executive Chairman and Global Scientific and Medical Officer, defendant Dr. Patrick Soon-Shion, materially overstated Anktiva's capabilities. The ImmunityBio class action lawsuit further alleges that on March 24, 2026, a warning letter (dated March 13, 2026) from the U.S. Food and Drug Administration to CEO Richard Adcock was publicized, stating that a "TV ad and podcast misbrand[ed] Anktiva and make the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act." The warning letter allegedly further stated that "[t]hese violations are concerning from a public health perspective because the promotional communications create a misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer." On this news, the price of ImmunityBio stock fell 21%, according to the complaint. THE LEAD PLAINTIFF PROCESS : The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired ImmunityBio publicly traded securities during the Class Period to seek appointment as lead plaintiff in the ImmunityBio class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the ImmunityBio investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the ImmunityBio shareholder class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the ImmunityBio class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: https://www.rgrdlaw.com/services-litigation-securities- fraud .html Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP Ken Dolitsky Michael Albert 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected] SOURCE Robbins Geller Rudman & Dowd LLP 21 % more press release views with  Request a Demo × Modal title

Kyndryl (KD) Faces Expanded Class Action; Investors See April 13 Deadline - Hagens Berman News provided by Hagens Berman Sobol Shapiro LLP Apr 03, 2026, 15:46 ET Share this article Share to X Share this article Share to X KD Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , April 3, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is alerting investors to an expanded securities class action filed against Kyndryl Holdings, Inc. (NYSE: KD ) . The new litigation expands the potential class of affected investors and introduces new allegations regarding the company's free cash flow reporting. REPORT YOUR KD INVESTMENT LOSSES TO HBSS . The newly filed action, Westchester Putnam Counties Heavy & Highway Laborers Local 60 Benefit Funds v. Kyndryl Holdings, Inc., et al. (S.D.N.Y.) , seeks to represent all persons and entities who purchased or otherwise acquired Kyndryl securities between August 1, 2024, and February 6, 2026 , inclusive (the "Expanded Class Period"). Kyndryl (KD) investors are encouraged to visit our updated case page to review the expanded allegations: www.hbsslaw.com/cases/kd , or view our latest video summary of the allegations: youtu.be/yBLSIN6NeQ0 "The litigation alleges that Kyndryl's much-touted free cash flow—a key indicator of the company's growth—was a mirage built on undisclosed and unsustainable cash management practices," said Reed Kathrein , the Hagens Berman partner leading the firm's investigation of the alleged claims in the pending litigation. "We are investigating whether the company used these practices to mask its true financial health, leading to the massive 55% value destruction when the CFO and General Counsel abruptly departed and the SEC's investigation became public." Kyndryl Holdings, Inc. (KD) Securities Class Action: Expanded Allegations While the initial complaint focused primarily on the failure to timely file financial reports and deficient internal controls, the expanded complaint alleges that throughout the Class Period, Kyndryl and its executives failed to disclose: Manipulated Cash Flow Metrics: That Kyndryl's reported free cash flow was artificially inflated by undisclosed and unsustainable cash management practices, rather than genuine operational strength. The August 2025 First Reveal: The complaint notes that the truth began to emerge on August 4, 2025 , when Kyndryl missed revenue and cash flow estimates, causing a 21% stock drop. Despite this, management allegedly continued to reassure investors about the "durability" of its financial condition. SEC Investigation & Executive Exodus: On February 9, 2026 , before the market opened, Kyndryl disclosed a voluntary document request from the SEC's Enforcement Division regarding its cash management practices. Simultaneously, the company announced the immediate departure of its CFO and General Counsel. Total Market Fallout: Following the February 9 announcement, Kyndryl's stock plummeted 55% , falling from $23.49 to $10.59 per share. Lead Plaintiff Deadline: April 13, 2026 Despite the filing of the new expanded complaint, the April 13, 2026 , deadline for investors to move for Lead Plaintiff remains unchanged. Submit Your Kyndryl (KD) Expanded Class Period Losses to HBSS Contact: Reed Kathrein at 844-916-0895 or email [email protected] If you'd like more information and answers to additional frequently asked questions about the firm's Kyndryl investigation, read more » Whistleblowers: Persons with non-public information regarding Kyndryl should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected] . About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com . the firm for updates and news at @ClassActionLaw . SOURCE Hagens Berman Sobol Shapiro LLP 21 % more press release views with  Request a Demo × Modal title

QURE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 News provided by Faruqi & Faruqi, LLP Apr 10, 2026, 11:34 ET Share this article Share to X Share this article Share to X Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in UniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . [You may also click here for additional information] NEW YORK , April 10, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against UniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE ) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com . As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the design of uniQure's Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; (2) Defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its BLA timeline to perform additional studies to supplement its BLA submission; and (3) as a result, Defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis. On November 3, 2025, uniQure disclosed that the FDA "currently no longer agrees" that data from the Phase I/II AMT-130 studies—when compared to an external control—would be adequate to support a BLA submission, notwithstanding the prespecified protocols and statistical analysis plans previously shared with the agency. The Company further admitted that, while it planned to urgently engage with the FDA, the timing of any BLA submission for AMT-130 was now unclear. This disclosure revealed the falsity of Defendants' prior representations that AMT-130 was on a near-term path toward accelerated approval. On this news, uniQure's ordinary share price fell $33.40 per share, or more than 49%, declining from a close of $67.69 on October 31, 2025 to $34.29 on November 3, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding UniQure's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the UniQure class action, go to www.faruqilaw.com/QURE or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . us for updates on LinkedIn , on X , or on Facebook . Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. SOURCE Faruqi & Faruqi, LLP As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the design of uniQure's Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; (2) Defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its BLA timeline to perform additional studies to supplement its BLA submission; and (3) as a result, Defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis. On November 3, 2025, uniQure disclosed that the FDA "currently no longer agrees" that data from the Phase I/II AMT-130 studies—when compared to an external control—would be adequate to support a BLA submission, notwithstanding the prespecified protocols and statistical analysis plans previously shared with the agency. The Company further admitted that, while it planned to urgently engage with the FDA, the timing of any BLA submission for AMT-130 was now unclear. This disclosure revealed the falsity of Defendants' prior representations that AMT-130 was on a near-term path toward accelerated approval. On this news, uniQure's ordinary share price fell $33.40 per share, or more than 49%, declining from a close of $67.69 on October 31, 2025 to $34.29 on November 3, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding UniQure's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the UniQure class action, go to www.faruqilaw.com/QURE or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . us for updates on LinkedIn , on X , or on Facebook . Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. SOURCE Faruqi & Faruqi, LLP --> 21 % more press release views with  Request a Demo × Modal title

Driven Brands Holdings Inc. Securities Fraud Class Actions Result of Erroneous Financial Statements and 39% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC News provided by Kahn Swick & Foti, LLC Apr 10, 2026, 22:14 ET Share this article Share to X Share this article Share to X Who is Involved : Driven Brands Holdings Inc. (NasdaqGS: DRVN) investors that purchased between May 3, 2023 and February 24, 2026 When to Act: Deadline to file Lead Plaintiff applications is May 8, 2026 Basis: Driven Brands shares fell on Disclosure of Erroneous Financial Statements NEW YORK and NEW ORLEANS , April 10, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 8, 2026 to file lead plaintiff applications in securities class action lawsuits against Driven Brands Holdings Inc. (NasdaqGS: DRVN) ("Driven" or the "Company"), if they purchased or otherwise acquired the Company's shares between May 3, 2023 and February 24, 2026, inclusive (the "Class Period"). These actions are pending in the United States District Courts for the Southern District of New York and Western District of North Carolina. Continue Reading Kahn Swick & Foti Speed Speed --> What You May Do If you purchased shares of Driven and would like to discuss your legal rights and how these cases might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( [email protected] ), or visit https://www.ksfcounsel.com/cases/nasdaqgs-drvn/ to learn more. If you wish to serve as a lead plaintiff in the class action, you must petition the Courts by May 8, 2026 . About the Lawsuits Driven and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On February 25, 2026, the Company disclosed that it had identified at least seven different categories of "material errors" in the Company's consolidated financial statements for fiscal years 2023 and 2024, as well as in quarterly periods in 2025, and that "such financial statements should not be relied upon and required restatement" and as a result, the Company would delay the filing of its Annual Report on Form 10-K for the fiscal year 2025 and need to restate its financials for fiscal years 2023, 2024, and the first three quarters of 2025. On this news, the price of Driven Brands' shares fell nearly 40%, from a close of $16.61 on February 24, 2026, to open at $9.99 on February 25, 2026. The first-filed case is Clark v. Driven Brands Holdings Inc., et al., No. 26-cv-01902. A subsequent case, City of Hollywood Police Officers' Retirement System v. Driven Brands Holdings Inc., et al., No. 26-cv-00283, expanded the class period. About Kahn Swick & Foti , LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit www.ksfcounsel.com . Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn SOURCE Kahn Swick & Foti, LLC 21 % more press release views with  Request a Demo × Modal title

Rosen Law Firm Encourages GSI Technology Inc. Investors to Inquire About Securities Class Action Investigation - GSIT News provided by THE ROSEN LAW FIRM, P. A. Apr 06, 2026, 21:48 ET Share this article Share to X Share this article Share to X NEW YORK , April 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GSI Technology Inc. (NASDAQ: GSIT ) resulting from allegations that GSI Technology may have issued materially misleading business information to the investing public. So What: If you purchased GSI Technology securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=52527 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. What is this about: On February 3, 2026, a post was issued on Stockwits in which it stated that "GSI is almost certainly hiding that their chip did not run Gemma-3 at all, only the pre-generation RAG phase. APU lack the MAC units required for matrix multiplication, which is critical for AI workloads." On this news, GSI Technology's stock price fell $1.08 per share, or 14.2%, to close at $6.52 per share on February 4, 2026. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

Rosen Law Firm Encourages Chanson International Holding Investors to Inquire About Securities Class Action Investigation - CHSN News provided by THE ROSEN LAW FIRM, P. A. Apr 04, 2026, 02:46 ET Share this article Share to X Share this article Share to X NEW YORK , April 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Chanson International Holding (NASDAQ: CHSN ) resulting from allegations that Chanson International Holding may have issued materially misleading business information to the investing public. So what: If you purchased Chanson International securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=56805 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. What is this about: Rosen Law Firm is investigating potential civil securities claims. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

Rosen Law Firm Encourages Barclays PLC Investors to Inquire About Securities Class Action Investigation - BCS News provided by THE ROSEN LAW FIRM, P. A. Apr 04, 2026, 13:03 ET Share this article Share to X Share this article Share to X NEW YORK , April 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Barclays PLC (NYSE: BCS ) resulting from allegations that Barclays PLC may have issued materially misleading business information to the investing public. So what: If you purchased Barclays PLC securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next : To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=23523 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email c [email protected] for information on the class action. What is this about: On February 27, 2026, Reuters published an article entitled "Wall Street hit by UK mortgage lender collapse, raising fears of more credit 'cockroaches." The article stated that lenders were "rocked by the implosion of little-known UK mortgage provider Market Financial Solutions Ltd ["MFS"], fuelling concerns about wider losses among banks and reviving warnings of more "cockroaches" in the booming private credit industry." It further stated that another publication "reported Barclays has a 600 million pound ($809.70 million) exposure to MFS." On this news, Barclays American Depositary Shares ("ADS") fell 3.99% on February 27, 2026, and 2.3% on March 2, 2026. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 c [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

Rosen Law Firm Encourages PennyMac Financial Services, Inc. Investors to Inquire About Securities Class Action Investigation - PFSI News provided by THE ROSEN LAW FIRM, P. A. Apr 06, 2026, 21:49 ET Share this article Share to X Share this article Share to X NEW YORK , April 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. (NYSE: PFSI ) resulting from allegations that PennyMac may have issued materially misleading business information to the investing public. So What: If you purchased PennyMac securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=51887 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. What is this about: On January 29, 2026, PennyMac filed a Current Report with the Securities Exchange Commission on Form 8-K announcing PennyMac's fourth quarter and full-year 2025 financial results. The report stated that PennyMac's "servicing segment pretax income was $37.3 million, down from $157.4 million in the prior quarter and $87.3 million in the fourth quarter of 2024," as well as "[retax income excluding valuation-related items was $47.8 million, down 70 percent from the prior quarter driven primarily by increased realization of mortgage servicing rights (MSR) cash flows as lower mortgage rates drove higher prepayment activity." On this news, PennyMac's stock price fell $49.78 per share, or 33.3%, to close at $99.92 per share on January 30, 2026. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

Super Micro Computer Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Super Micro Computer, Inc. - SMCI News provided by ClaimsFiler Apr 03, 2026, 22:02 ET Share this article Share to X Share this article Share to X NEW ORLEANS , April 3, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against Super Micro Computer, Inc. ("Super Micro" or the "Company") (NasdaqGS: SMCI), if they purchased or otherwise acquired the Company's securities between April 30, 2024 and March 19, 2026, (the "Class Period"). This action is pending in the United States District Court for the Northern District of California. Get Help Super Micro investors should visit us at https://claimsfiler.com/cases/nasdaq-smci-4/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit Super Micro and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On March 19, 2026, post-market, the U.S. Department of Justice announced the unsealing of an indictment against three individuals associated with the Company, Yih-Shyan Liaw (the Company's co-founder, director, and Senior Vice President of Business Development), Ruei-Tsang Chang ("a general manager in the [Super Micro's] Taiwan office)," and Ting-Wei Sun ("a third-party broker and fixer"), for engaging in a "scheme to divert massive quantities of servers housing U.S. artificial intelligence technology to customers in China" violating U.S. export control laws, in order to "drive sales and generate revenues in violation of U.S. law" and enabled the sale of "approximately $2.5 billion worth of servers" between 2024 and 2025. On this news, the price of Super Micro's shares fell $10.26, or 33.3%, to close at $20.53 per share on March 20, 2026. The case is Bhuva v. Super Micro Computer, Inc., et al., Case No. 26-cv-02606. About ClaimsFiler ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations. To learn more about ClaimsFiler, visit www.claimsfiler.com . SOURCE ClaimsFiler 21 % more press release views with  Request a Demo × Modal title

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX News provided by ClaimsFiler Apr 03, 2026, 22:03 ET Share this article Share to X Share this article Share to X NEW ORLEANS , April 3, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio , Inc. (NasdaqGS: IBRX) ("ImmunityBio" or the "Company"), if they purchased or otherwise acquired the Company's securities between January 19, 2026 and March 24, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Central District of California. Get Help ImmunityBio investors should visit us at https://claimsfiler.com/cases/nasdaq-ibrx-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit ImmunityBio and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On March 24, 2026, a warning letter dated March 13, 2026, from the U.S. Food and Drug Administration to CEO Richard Adcock was made public, stating that a television advertisement and podcast misrepresented Anktiva and resulted in its distribution violating the Federal Food, Drug, and Cosmetic Act. The letter also reportedly noted that the violations "are concerning from a public health perspective because the promotional communications create a misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer." On this news, the price of ImmunityBio's shares fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026. The case is Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261. About ClaimsFiler ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations. To learn more about ClaimsFiler, visit www.claimsfiler.com . SOURCE ClaimsFiler 21 % more press release views with  Request a Demo × Modal title

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Super Micro Computer, Inc. (SMCI) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit News provided by Robbins Geller Rudman & Dowd LLP Apr 03, 2026, 22:30 ET Share this article Share to X Share this article Share to X SAN DIEGO , April 3, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Super Micro class action lawsuit – captioned Bhuva v. Super Micro Computer, Inc. , No. 26-cv-02606 (N.D. Cal.) – seeks to represent purchasers or acquirers of Super Micro Computer, Inc. (NASDAQ: SMCI ) securities and charges Super Micro as well as certain of Super Micro's top executive officers with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Super Micro class action lawsuit, please provide your information here: https://www.rgrdlaw.com/cases-super-micro-computer-class-action-lawsuit-smci.html You can also contact attorney Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected] . Lead plaintiff motions for the Super Micro class action lawsuit must be filed with the court no later than May 26, 2026. CASE ALLEGATIONS : Super Micro, together with its subsidiaries, develops and sells server and storage solutions based on modular and open-standard architecture. The Super Micro class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) a significant portion of Super Micro's sales of servers were to companies based in China; (ii) these transactions violated U.S. export control laws; and (iii) there were material weaknesses in Super Micro's controls to ensure compliance with applicable export control laws and regulations. The Super Micro class action lawsuit further alleges that on March 19, 2026, the U.S. Department of Justice ("DOJ") announced the unsealing of an indictment against three individuals associated with Super Micro for engaging in a "scheme to divert massive quantities of servers housing U.S. artificial intelligence technology to customers in China" in violation of U.S. export control laws. The DOJ announcement allegedly stated these activities were done "all to drive sales and generate revenues in violation of U.S. law" and enabled the sale of "approximately $2.5 billion worth of servers" between 2024 and 2025. According to the DOJ, Yih-Shyan Liaw (Super Micro's co-founder, director, and Senior Vice President of Business Development), Ruei-Tsang Chang ("a general manager in [Super Micro's] Taiwan office"), and Ting-Wei Sun ("a third-party broker and "'fixer'") "conspired to systematically divert [Super Micro's] servers with certain GPUs to China without a license to do so from the U.S. Department of Commerce," the complaint alleges . On this news, the price of Super Micro stock fell more than 33%, according to the Super Micro class action lawsuit. THE LEAD PLAINTIFF PROCESS : The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Super Micro securities during the class period to seek appointment as lead plaintiff in the Super Micro class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Super Micro investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Super Micro shareholder class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Super Micro class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: https://www.rgrdlaw.com/services-litigation-securities- fraud .html Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP Ken Dolitsky Michael Albert 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected] SOURCE Robbins Geller Rudman & Dowd LLP 21 % more press release views with  Request a Demo × Modal title

GEMI INVESTOR ALERT: Gemini (GEMI) Post-IPO Meltdown Sparks Securities Class Action as Investors Seek Recovery - Hagens Berman News provided by Hagens Berman Sobol Shapiro LLP Apr 03, 2026, 22:08 ET Share this article Share to X Share this article Share to X SAN FRANCISCO , April 3, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Gemini Space Station, Inc. (NASDAQ: GEMI ) and its top executives, including founders Cameron and Tyler Winklevoss. The litigation follows a series of disclosures that have caused the company's stock to trade more than 75% below its initial public offering (IPO) price. The firm urges Gemini investors who suffered significant losses to: CONTACT HBSS NOW TO DISCUSS THEIR RIGHTS . The lawsuit, Methvin v. Gemini Space Station, Inc., et al. , No. 1:26-cv-02261 , was filed in the U.S. District Court for the Southern District of New York. The action seeks to recover losses for all persons and entities who purchased or otherwise acquired Gemini common stock pursuant and/or traceable to the Company's September 12, 2025 initial public offering ("IPO") , and/or Gemini securities between September 12, 2025, and February 17, 2026 , inclusive. Investors who purchased Gemini (GEMI) securities are encouraged to visit: www.hbsslaw.com/cases/gemini "We're examining whether Gemini may have misled investors by portraying the company as focused on international exchange growth while allegedly failing to disclose an imminent pivot to prediction markets," said Reed Kathrein , the Hagens Berman partner leading the firm's investigation of the alleged claims in the pending class action. Summary of GEMI Securities Class Action's Allegations: The "Gemini 2.0" Pivot The complaint alleges that Gemini made material misstatements and omitted critical information, including in its IPO materials. Overstated Viability: Gemini allegedly overstated the viability of Gemini's core cryptocurrency exchange platform and its ability to scale international operations as a foundation for sustained growth. The Abrupt Pivot: On February 5, 2026, Gemini announced a corporate pivot to Gemini 2.0, revealing that the company would shift focus to prediction markets , exit the United Kingdom and Australia, and reduce its workforce by 25%. Mass Executive Exodus: On February 17, 2026, Gemini announced the simultaneous "parting of ways" with its COO (Marshall Beard) , CFO (Dan Chen) , and Chief Legal Officer (Tyler Meade) —less than six months after the IPO. 75% Value Destruction: Following these disclosures and the announcement of a projected $602 million net loss for 2025, Gemini's stock price fell to below $7.00 per share , representing a decline of more than 75% from the $28.00 IPO price . Critical Deadline: May 18, 2026 If you purchased Gemini common stock in or traceable to the September 2025 IPO , or during the Class Period , you have until May 18, 2026 , to ask the Court to appoint you as Lead Plaintiff. Submit Your GEMIN Investment Losses Now Contact: Reed Kathrein at 844-916-0895 or email [email protected] If you'd like more information and answers to frequently asked questions about the Gemini case and the firm's investigation, read more » Whistleblowers: Persons with non-public information regarding Gemini should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected] . About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com . the firm for updates and news at @ClassActionLaw . SOURCE Hagens Berman Sobol Shapiro LLP 21 % more press release views with  Request a Demo × Modal title

Gemini Space Station, Inc. Notice of May 18, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline News provided by Kahn Swick & Foti, LLC Apr 10, 2026, 22:19 ET Share this article Share to X Share this article Share to X NEW YORK and NEW ORLEANS , April 10, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Gemini Space Station , Inc. ("Gemini" or the "Company") (NasdaqGS: GEMI) of a class action securities lawsuit. Continue Reading Kahn Swick & Foti Speed Speed --> CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Gemini Class A common stock pursuant and/or traceable to the Company's September 12, 2025 initial public offering ("IPO"), and/or Gemini securities between September 12, 2025 and February 17, 2026 (the "Class Period"). the link below to get more information and be contacted by a member of our team: https://www.ksfcounsel.com/cases/nasdaqgs-gemi/ Gemini investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( [email protected] ), or visit https://www.ksfcounsel.com/cases/nasdaqgs-gemi/ to learn more. CASE DETAILS: According to the Complaint, Gemini and certain of its executives are charged with failing to disclose material information in connection with its Offering Documents in Support of its IPO and/or during the Class Period, violating federal securities laws. The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) the Company had overstated the viability of its core business as a crypto platform; (ii) the Company had overstated its commitment to and/or the viability of growing its business through expanding its international operations; (iii) accordingly, the Company's post-IPO financial and business prospects were overstated; (iv) all of the foregoing raised a non-speculative risk that the Company was poised for an expensive and disruptive restructuring; and (v) as a result, the Offering Documents and defendants' public statements throughout the class period were materially false and misleading at all relevant times. The case is Methvin v. Gemini Space Station, Inc., et al., No. 26-cv-02261. WHAT TO DO? If you invested in Gemini and suffered a loss during the relevant time frame, you have until May 18, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff. About Kahn Swick & Foti , LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit www.ksfcounsel.com . Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn SOURCE Kahn Swick & Foti, LLC 21 % more press release views with  Request a Demo × Modal title

MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Apr 05, 2026, 16:59 ET Share this article Share to X Share this article Share to X NEW YORK , April 5, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO ) between June 5, 2023 and December 26, 2025 (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. So What: If you purchased Mereo ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Mereo class action, go to https://rosenlegal.com/submit-form/?case_id=52452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants provided investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested patients and in the study itself to put setrusumab in an opportunity to succeed in reaching statistical significance of this key endpoint. The defendants, the lawsuit claims, provided these positive statements to investors while, at the same time, disseminating false and materially misleading statements and/or concealing material adverse facts concerning the true state of the Phase 3 ORBIT and COSMIC programs; neither of which hit their primary endpoints of reducing annualized clinical fracture rate compared to the placebo or bisphosphonate control groups, respectively. Such statements absent these material facts caused investors to purchase Mereo's ADSs at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Mereo class action, go to https://rosenlegal.com/submit-form/?case_id=52452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

IBRX INVESTOR ALERT: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman News provided by Hagens Berman Sobol Shapiro LLP Apr 03, 2026, 22:15 ET Share this article Share to X Share this article Share to X SAN FRANCISCO , April 3, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX ) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scientific and Medical Officer (Dr. Patrick Soon-Shiong) regarding ImmunityBio's lead biologic product (Anktiva), which the FDA said were misleading efficacy claims. This news drove the price of ImmunityBio shares down over 21% on March 24, 2026. The developments have prompted national shareholders rights firm Hagens Berman to investigate claims that ImmunityBio violated the federal securities laws. The firm urges investors in ImmunityBio who suffered significant losses to submit your losses now . The firm also encourages witnesses who may be able to assist in the investigation to contact its attorneys. Class Period: Jan. 19, 2026 – Mar. 24, 2026 Lead Plaintiff Deadline: May 26, 2026 Visit: www.hbsslaw.com/investor- fraud /ibrx Contact the Firm Now: [email protected] 844-916-0895 ImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. The company's Anktiva is an FDA-approved immunotherapy used with Bacillus Calmette-Guérin ("BCG") to treat non-muscle invasive bladder cancer ("NMIBC"). The lawsuit is focused on the propriety of ImmunityBio's claims about Anktiva's efficacy for treating other forms of cancer. On January 19, 2026, a direct-to-consumer podcast ("Is the FDA BLOCKING Life Saving Cancer Treatments?") aired, featuring Soon-Shiong. During the podcast, he said in part that, while Anktiva is approved for bladder cancer, "it actually can treat all cancers." Soon-Shiong made other questionable claims about Anktiva, which together were flagged by the FDA as misleading. On March 24, 2026, the financial press reported that the FDA sent a warning letter to ImmunityBio over claims made in the podcast and a TV ad. The warning letter states the "FDA has determined that the TV ad and podcast are false or misleading." The FDA explained, "the promotional materials create the misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer." In addition, the FDA warned that "the representations in the TV ad and podcast misleadingly suggest that Anktiva will allow all NIMBC patients treated with Anktiva to be cancer-free for the long term, when this has not been demonstrated" and "we are not aware of data that support the efficacy claims and representations that Anktiva can 'cure' cancer." The FDA also said ImmunityBio's promotional materials were misleading because "they fail to provide material information regarding Anktiva's full FDA-approved indication." Lastly, the FDA warned that ImmunityBio's "consistent and pervasive misleading efficacy claims and representations presented across promotional materials on different platforms are especially concerning from a public health perspective, given they grossly misrepresent the benefits of Anktiva." This news drove the price of ImmunityBio shares down over 21% on March 24, 2026, erasing nearly $2 billion of the company's market capitalization. "We're investigating claims that ImmunityBio intentionally misled investors about Anktiva efficacy and indications," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation. If you invested in ImmunityBio and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now » If you'd like more information and answers to frequently asked questions about the ImmunityBio case and the firm's investigation, read more » Whistleblowers: Persons with non-public information regarding ImmunityBio should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected] . About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com . the firm for updates and news at @ClassActionLaw . SOURCE Hagens Berman Sobol Shapiro LLP 21 % more press release views with  Request a Demo × Modal title

CIGL Investors Have Opportunity to Lead Concorde International Group Ltd. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Mar 31, 2026, 15:35 ET Share this article Share to X Share this article Share to X NEW YORK , March 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Concorde International Group Ltd. (NASDAQ: CIGL ) between April 21, 2025 and July 14, 2025, inclusive (the "Class Period"), of the important May 20, 2026 lead plaintiff deadline. So what: If you purchased Concorde securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Concorde class action, go to https://rosenlegal.com/submit-form/?case_id=56776 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Concorde was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) Concorde's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price; and (4) as a result of the foregoing, defendants' positive statements about Concorde's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. To join the Concorde class action, go to https://rosenlegal.com/submit-form/?case_id=56776 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

Paysafe Limited (PSFE) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit News provided by Glancy Prongay Wolke & Rotter LLP Apr 03, 2026, 15:24 ET Share this article Share to X Share this article Share to X LOS ANGELES , April 3, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Paysafe Limited ("Paysafe" or the "Company") (NYSE: PSFE ). IF YOU SUFFERED A LOSS ON YOUR PAYSAFE INVESTMENTS, CLICK HERE BEFORE APRIL 7, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About? The complaint filed alleges that, between March 4, 2025 and November 12, 2025, Defendants failed to disclose to investors: (1) Paysafe's ecommerce business had significant exposure to a single high risk client; (2) as a result, the Company's credit loss reserves and/or write-offs were understated; (3) Paysafe had an undisclosed issue with higher risk Merchant Category Codes, making its client services difficult to bank; (4) the foregoing issues were likely to have a material negative impact on the Company's revenue growth and overall revenue mix; (5) as a result, Paysafe was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (6) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay Wolke & Rotter LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: [email protected] Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at www.glancylaw.com . us for updates on LinkedIn , Twitter , or Facebook . If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact Us: Glancy Prongay Wolke & Rotter LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 Charles Linehan Email: [email protected] Telephone: 310-201-9150 Toll-Free: 888-773-9224 Visit our website at: www.glancylaw.com . SOURCE Glancy Prongay Wolke & Rotter LLP 21 % more press release views with  Request a Demo × Modal title

Enphase Energy, Inc. Notice of April 20, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline News provided by Kahn Swick & Foti, LLC Apr 10, 2026, 22:17 ET Share this article Share to X Share this article Share to X NEW YORK and NEW ORLEANS , April 10, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Enphase Energy , Inc. ("Enphase" or the "Company") (NasdaqGM: ENPH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Enphase who were adversely affected by alleged securities fraud between April 22, 2025 and October 28, 2025. the link below to get more information and be contacted by a member of our team: Continue Reading Kahn Swick & Foti Speed Speed --> https://www.ksfcounsel.com/cases/nasdaqgm-enph/ Enphase investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( [email protected] ), or visit https://www.ksfcounsel.com/cases/nasdaqgm-enph/ to learn more. CASE DETAILS: According to the Complaint, Enphase and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company had overstated its ability to manage its channel inventory; (ii) the Company had overstated its ability to offset the impacts resulting from the termination of the Residential Clean Energy Credit pursuant to Internal Revenue Code Section 25D; and (iii) as a result, the Company overstated its financial and operational prospects. The case is Tripathi v. Enphase Energy, Inc., No. 26-cv-01380. WHAT TO DO? If you invested in Enphase and suffered a loss during the relevant time frame, you have until April 20, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff. About Kahn Swick & Foti , LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit www.ksfcounsel.com . Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn SOURCE Kahn Swick & Foti, LLC 21 % more press release views with  Request a Demo × Modal title

TCOM Investors Have Opportunity to Lead Trip.com Group Limited Securities Fraud Lawsuit First Filed by the Rosen Law Firm News provided by THE ROSEN LAW FIRM, P. A. Apr 05, 2026, 15:31 ET Share this article Share to X Share this article Share to X NEW YORK , April 5, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Trip.com Group Limited (NASDAQ: TCOM ) between April 30, 2024 and January 13, 2026, both dates inclusive (the "Class Period"), of the important May 11, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Trip,com securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Trip.com class action, go to https://rosenlegal.com/submit-form/?case_id=50668 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendants recklessly understated the regulatory risk facing Trip.com as a result of its monopolistic business activities; and (2) as a result, defendants' statements about Trip.com's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Trip.com class action, go to https://rosenlegal.com/submit-form/?case_id=50668 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40 th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

CORT INVESTOR ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss News provided by Hagens Berman Sobol Shapiro LLP Mar 30, 2026, 15:56 ET Share this article Share to X Share this article Share to X Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 Deadline SAN FRANCISCO , March 30, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT ) that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026 . The firm urges Corcept investors who suffered significant losses to contact the firm now to discuss their rights . The lawsuit, Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., et al. , No. 26-cv-01525 , was filed in the U.S. District Court for the Northern District of California. The action seeks to recover losses for all persons and entities who purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025 (the "Class Period"). Investors in Corcept (CORT) are encouraged to visit the Hagens Berman's CORT Case Page to review the allegations: www.hbsslaw.com/cases/corcept "The heart of the Corcept case is a classic 'information gap' between what the company told the public and what the FDA was reportedly telling the company behind closed doors," said Reed Kathrein , the Hagens Berman partner leading the firm's investigation. Summary of the Allegations: The "Relacorilant" Disclosure Failure The filed complaint in Allegheny County v. Corcept alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the company's lead drug candidate, relacorilant , by failing to disclose: Concealed FDA Concerns: That during pre-submission meetings in 2024 and early 2025, the FDA warned Corcept on several occasions that its clinical data lacked sufficient evidence of effectiveness to support a New Drug Application (NDA). Misleading Narrative: That defendants continued to tout Phase 3 results, despite knowing the FDA viewed the data as fundamentally flawed. The CRL Bombshell: On December 31, 2025, Corcept revealed it had received a Complete Response Letter (CRL) from the FDA. The agency concluded it could not arrive at a favorable benefit-risk assessment for relacorilant due to an "insufficient" evidentiary record. 50% Market Crash: Following this disclosure, Corcept's stock price plummeted from $70.20 on December 30, 2025, to close at $34.80.06 on December 31, 2025—erasing nearly $2.5 billion in market capitalization in a single day. View our latest video summary of the allegations: youtube.com/watch?v=vMk3jcOV3Ng Critical Deadline: April 21, 2026 If you purchased Corcept common stock during the Class Period, you have until April 21, 2026 , to ask the Court to appoint you as Lead Plaintiff. SUBMIT YOUR CORT LOSSES NOW Contact: Reed Kathrein at 844-916-0895 or email [email protected] If you'd like more information and answers to other frequently asked questions about the Corcept case and our investigation, read more » Whistleblowers: Persons with non-public information regarding Corcept should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected] . About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com . the firm for updates and news at @ClassActionLaw . SOURCE Hagens Berman Sobol Shapiro LLP 21 % more press release views with  Request a Demo × Modal title

Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GOSS News provided by DJS Law Group LLP Apr 03, 2026, 01:50 ET Share this article Share to X Share this article Share to X LOS ANGELES , April 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of GOSS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: June 16, 2025 to February 20, 2026 DEADLINE: June 1, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Gossamer misled investors by concealing facts about issues with its Phase 3 PROSERA study. Based on these facts, Gossamer's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email: [email protected] SOURCE DJS Law Group LLP 21 % more press release views with  Request a Demo × Modal title

Driven Brands Holdings Inc. (DRVN) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit News provided by The Law Offices of Frank R. Cruz, Los Angeles Apr 03, 2026, 16:00 ET Share this article Share to X Share this article Share to X LOS ANGELES , April 3, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Driven Brands Holdings Inc. ("Driven Brands" or the "Company") (NASDAQ: DRVN ) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN DRIVEN BRANDS HOLDINGS INC. (DRVN), CLICK HERE BEFORE MAY 8, 2026 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. What Is The Lawsuit About? The complaint filed alleges that, between May 9, 2023 and February 24, 2026, Defendants failed to disclose to investors that: (1) there were errors relating to the recording of leases which primarily impacted the right of use assets and right of use liabilities recorded in the consolidated balance sheet as of December 28, 2024, and September 27, 2025; (2) there were errors in reporting opening and ending cash balances and operating cash flows, which resulted in overstatements of cash and revenue and understatement of selling, general and administrative expense in consolidated statement of operations for fiscal years 2023 and 2024; (3) supply and other expenses were improperly presented as company-operated store expenses in fiscal years 2023 and 2024; (4) other errors were identified relating to income tax provision, supply and other revenue, fixed assets, cloud computing, lease cash applications, and balance sheet and income statement misclassifications; (6) the Company improperly recognized revenue in Driven Brands' ATI business; and (7) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. The Law Offices of Frank R. Cruz, Email us at: [email protected] Call us at: 310-914-5007 Visit our website at: www.frankcruzlaw.com us for updates on Twitter: twitter.com/FRC_LAW . If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. SOURCE The Law Offices of Frank R. Cruz, Los Angeles 21 % more press release views with  Request a Demo × Modal title

Super Micro Computer, Inc. Notice of May 26, 2026 Application Deadline for Class Action Lawsuits - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline News provided by Kahn Swick & Foti, LLC Apr 10, 2026, 22:00 ET Share this article Share to X Share this article Share to X NEW YORK and NEW ORLEANS , April 10, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Super Micro Computer , Inc. ("Super Micro" or the "Company") (NasdaqGS: SMCI) of class action securities lawsuits. CLASS DEFINITION: The lawsuits seeks to recover losses on behalf of investors of Super Micro who were adversely affected by alleged securities fraud between February 2, 2024 and March 19, 2026. the link below to get more information and be contacted by a member of our team: Continue Reading Kahn Swick & Foti Speed Speed --> https://ksfcounsel.com/cases/nasdaqgs-smci-2/ Super Micro investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( [email protected] ), or visit https://ksfcounsel.com/cases/nasdaqgs-smci-2/ to learn more. CASE DETAILS: According to the Complaint, Super Micro and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On March 19, 2026, post-market, the U.S. Department of Justice announced the unsealing of an indictment against three individuals associated with the Company, Yih-Shyan Liaw (the Company's co-founder, director, and Senior Vice President of Business Development), Ruei-Tsang Chang ("a general manager in the [Super Micro's] Taiwan office)," and Ting-Wei Sun ("a third-party broker and fixer"), for engaging in a "scheme to divert massive quantities of servers housing U.S. artificial intelligence technology to customers in China" violating U.S. export control laws, in order to "drive sales and generate revenues in violation of U.S. law" and enabled the sale of "approximately $2.5 billion worth of servers" between 2024 and 2025. On this news, the price of Super Micro's shares fell $10.26, or 33.3%, to close at $20.53 per share on March 20, 2026. The first-filed case is Bhuva v. Super Micro Computer, Inc., et al., No. 26-cv-02606. A subsequent case, City of Hialeah Employees Retirement System v. Super Micro Computer, Inc., et al., No. 26-cv-3018, expanded the class period. WHAT TO DO? If you invested in Super Micro and suffered a loss during the relevant time frame, you have until May 26, 2026 to request that the Courts appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff. About Kahn Swick & Foti , LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit www.ksfcounsel.com . Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn SOURCE Kahn Swick & Foti, LLC 21 % more press release views with  Request a Demo × Modal title

Apollo Global Management, Inc. Securities Fraud Class Action Result of Undisclosed Relationship with Jeffrey Epstein and 16% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC News provided by Kahn Swick & Foti, LLC Apr 10, 2026, 22:07 ET Share this article Share to X Share this article Share to X NEW YORK and NEW ORLEANS , April 10, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 1, 2026 to file lead plaintiff applications in a securities class action lawsuit against Apollo Global Management , Inc. (NYSE: APO ) ("Apollo" or the "Company"), if they purchased or otherwise acquired the Company's securities between May 10, 2021 and February 21, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York. Continue Reading Kahn Swick & Foti Speed Speed --> What You May Do If you purchased securities of Apollo and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( [email protected] ), or visit https://www.ksfcounsel.com/cases/nyse-apo/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 1, 2026 . About the Lawsuit Apollo and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company's leadership figures, including defendants Marc Rowan and Leon Black, frequently communicated with Jeffrey Epstein in the 2010s regarding the Company's business; (ii) as a result, the Company's assertion that Apollo Global had never done business with Jeffrey Epstein was untrue; (iii) because of the entanglement between Apollo Global's leaders and Jeffrey Epstein, the harm to the Company's reputation was more than a mere possibility; and (iv) as a result, the Company's statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. The case is Feldman v. Apollo Global Management, Inc., et al., Case No. 26-cv-01692. About Kahn Swick & Foti , LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit www.ksfcounsel.com . Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn SOURCE Kahn Swick & Foti, LLC 21 % more press release views with  Request a Demo × Modal title

SMCI UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Super Micro (SMCI) Investors of Securities Class Action Deadline on May 26, 2026 News provided by Faruqi & Faruqi, LLP Apr 10, 2026, 11:39 ET Share this article Share to X Share this article Share to X Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Super Micro To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Super Micro between February 2, 2024 and March 19, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . [You may also click here for additional information] NEW YORK , April 10, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Super Micro Computer, Inc. ("Super Micro" or the "Company") (NASDAQ: SMCI ) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Watch our latest video highlighting the key allegations: https://youtu.be/gG-0sMrxN6Q James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com . As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) a significant portion of the Company's sales of servers were to companies based in China; (2) these transactions violated U.S. export control laws; (3) there were material weaknesses in the Company's controls to ensure compliance with applicable export control laws and regulations; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On March 19, 2026, after the market closed, the U.S. Justice Department announced the unsealing of an indictment against three individuals associated with Super Micro for engaging in a "scheme to divert massive quantities of servers housing U.S. artificial intelligence technology to customers in China" in violation of U.S. export control laws. The announcement stated these activities were done " all to drive sales and generate revenues in violation of U.S. law " and enabled the sale of "approximately $2.5 billion worth of servers" between 2024 and 2025. According to the DOJ, Yih-Shyan Liaw (the Company's co-founder, director, and Senior Vice President of Business Development), Ruei-Tsang Chang ("a general manager in the [Super Micro's] Taiwan office"), and Ting-Wei Sun (a third-party broker and "fixer") " conspired to systematically divert [Super Micro's] servers with certain GPUs to China without a license to do so from the U.S. Department of Commerce ." According to media reports, the GPUs are Nvidia's most advanced AI chips. On the same date, Super Micro released a statement seeking to distance itself from the indictment by noting that the Company has not directly been named a defendant in the Justice Department action. However, the Company confirmed that the charged individuals had been affiliated with Super Micro, stating that the two employees were placed on administrative leave and the contractor's relationship was terminated. The statement claimed the "Company has been cooperating fully with the government's investigation and will continue to do so." On this news, Super Micro's stock price fell $10.26, or 33.3%, to close at $20.53 per share on March 20, 2026, on unusually heavy trading volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Super Micro's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Super Micro class action, go to www.faruqilaw.com/SMCI or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . us for updates on LinkedIn , on X , or on Facebook . Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. SOURCE Faruqi & Faruqi, LLP Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com . As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) a significant portion of the Company's sales of servers were to companies based in China; (2) these transactions violated U.S. export control laws; (3) there were material weaknesses in the Company's controls to ensure compliance with applicable export control laws and regulations; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On March 19, 2026, after the market closed, the U.S. Justice Department announced the unsealing of an indictment against three individuals associated with Super Micro for engaging in a "scheme to divert massive quantities of servers housing U.S. artificial intelligence technology to customers in China" in violation of U.S. export control laws. The announcement stated these activities were done " all to drive sales and generate revenues in violation of U.S. law " and enabled the sale of "approximately $2.5 billion worth of servers" between 2024 and 2025. According to the DOJ, Yih-Shyan Liaw (the Company's co-founder, director, and Senior Vice President of Business Development), Ruei-Tsang Chang ("a general manager in the [Super Micro's] Taiwan office"), and Ting-Wei Sun (a third-party broker and "fixer") " conspired to systematically divert [Super Micro's] servers with certain GPUs to China without a license to do so from the U.S. Department of Commerce ." According to media reports, the GPUs are Nvidia's most advanced AI chips. On the same date, Super Micro released a statement seeking to distance itself from the indictment by noting that the Company has not directly been named a defendant in the Justice Department action. However, the Company confirmed that the charged individuals had been affiliated with Super Micro, stating that the two employees were placed on administrative leave and the contractor's relationship was terminated. The statement claimed the "Company has been cooperating fully with the government's investigation and will continue to do so." On this news, Super Micro's stock price fell $10.26, or 33.3%, to close at $20.53 per share on March 20, 2026, on unusually heavy trading volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Super Micro's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Super Micro class action, go to www.faruqilaw.com/SMCI or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . us for updates on LinkedIn , on X , or on Facebook . Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. SOURCE Faruqi & Faruqi, LLP --> 21 % more press release views with  Request a Demo × Modal title

Trade Desk Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of The Trade Desk, Inc. - TTD News provided by Kahn Swick & Foti, LLC Apr 10, 2026, 22:00 ET Share this article Share to X Share this article Share to X NEW YORK and NEW ORLEANS , April 10, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC ("KSF"), announces that KSF has commenced an investigation into The Trade Desk , Inc. ("Trade Desk" or the "Company") (NasdaqGM: TTD). On February 12, 2025, the Company announced its financial results for the fourth quarter and full year of 2024, disclosing 4Q 2024 revenue of $741 million - below its previously issued guidance of $756 million and analysts' estimates of $759.8 million because, contrary to prior assurances of a seamless conversion, it had not yet transitioned all of its clients to the new advertising platform, Kokai, and was still "maintaining 2 systems, Solimar and Kokai," and that "Kokai rolled out slower than anticipated," but that "in some cases, the slower Kokai rollout was deliberate." Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing. KSF's investigation is focusing on whether Trade Desk's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws. If you have information that would assist KSF in its investigation, or have been a long-term holder of Trade Desk shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn ( [email protected] ), or visit https://www.ksfcounsel.com/cases/nasdaqgm-ttd/ to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit www.ksfcounsel.com . Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn SOURCE Kahn Swick & Foti, LLC 21 % more press release views with  Request a Demo × Modal title

ODDITY Tech Ltd. (ODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit News provided by Law Offices of Howard G. Smith Apr 03, 2026, 15:23 ET Share this article Share to X Share this article Share to X BENSALEM, Pa. , April 3, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against ODDITY Tech Ltd. ("Oddity" or the "Company") (NASDAQ: ODD ). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ODDITY TECH LTD. (ODD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MAY 11, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected] , by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com . What Is The Lawsuit About? The complaint filed alleges that, between February 26, 2025 and February 24, 2026, Defendants failed to disclose to investors that: (1) due to an algorithm change by Oddity's largest advertising partner, Oddity's advertisements were being diverted to lower quality auctions at abnormally high costs; (2) the foregoing significantly increased Oddity's customer acquisition costs, thereby negatively impacting Oddity's business and financial prospects; (3) accordingly, Defendants overstated the overall strength, stability, and sustainability of Oddity's digital operating model and/or market position; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact: Howard G. Smith, Esq., Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Call us at: (215) 638-4847 Email us at: [email protected] , Visit our website at: www.howardsmithlaw.com . To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact Us: Law Offices of Howard G. Smith Howard G. Smith, Esquire 215-638-4847 [email protected] www.howardsmithlaw.com SOURCE Law Offices of Howard G. Smith 21 % more press release views with  Request a Demo × Modal title

ODD INVESTOR ALERT: ODDITY Tech. (ODD) Sued After Shares Plunge 49% on AI Platform Disruption and Revenue Decline -- Hagens Berman News provided by Hagens Berman Sobol Shapiro LLP Apr 03, 2026, 22:06 ET Share this article Share to X Share this article Share to X SAN FRANCISCO , April 3, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against ODDITY Tech. Ltd. (NASDAQ: ODD ) , seeking to represent investors who purchased ODDITY securities between February 26, 2025 and February 24, 2026. The lawsuit follows the 49% decline in the price of ODDITY American Depositary Shares on February 25, 2026. The selloff, which wiped out over $600 million dollars of the company's market capitalization, was triggered by the company's announcement that it expects a whopping 30% year-over-year decline in its Q1 2026 revenue. The development and severe market reaction have prompted national shareholders rights firm Hagens Berman to investigate claims that ODDITY violated the federal securities laws. The firm urges investors in ODDITY who suffered significant losses to submit your losses now . The firm also encourages witnesses who may be able to assist in the investigation to contact its attorneys. Class Period: Feb. 26, 2025 – Feb. 24, 2026 Lead Plaintiff Deadline: May 11, 2026 Visit: www.hbsslaw.com/investor- fraud /odd Contact the Firm Now: [email protected] 844-916-0895 ODDITY Tech. Ltd. (ODD) Securities Class Action: The lawsuit is focused on ODDITY's repeated touting of its AI-driven online platform, which the company assured investors would "sustain our high-growth and attractive margin profile[.]" The complaint alleges that ODDITY made false and misleading statements while failing to disclose crucial information to investors, including an algorithm change by the company's largest advertising partner which resulted in the diversion of ODDITY's advertisements to lower quality auctions at abnormally high costs. This, in turn, significantly increased ODDITY's customer acquisition costs and negatively affected the company's business and financial prospects. In addition, the complaint alleges , the foregoing resulted in the company's overstating the overall strength, stability, and sustainability of ODDITY's digital operating model. Investors' expectations were dashed on February 25, 2026, when ODDITY announced its Q4 and FY 2025 financial results and revealed that "we experienced a dislocation in our account with our largest advertising partner that we believe was driven by algorithm changes which diverted us to lower quality auctions at abnormally high costs" that drove new user acquisition costs significantly higher. During the related earnings call, an analyst pressed management about when ODDITY first knew of the dislocation, but management would only say that they had "observed that something was different in the second half of 2025" – that is, without acknowledging when the issue actually started. As concerning, ODDITY quantified the effects of the dislocation, saying that Q1 2026 revenue would decline 30% year-over-year. "We're investigating when ODDITY first knew of the dislocation issue and whether it may have intentionally misled investors about the true strength of its AI growth-driver," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation. If you invested in ODDITY and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now » If you'd like more information and answers to additional frequently asked questions about the ODDITY case and the firm's investigation, read more » Whistleblowers: Persons with non-public information regarding ODDITY should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected] . About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com . the firm for updates and news at @ClassActionLaw . SOURCE Hagens Berman Sobol Shapiro LLP 21 % more press release views with  Request a Demo × Modal title

Lakeland Industries, Inc. (LAKE) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit News provided by The Law Offices of Frank R. Cruz, Los Angeles Apr 03, 2026, 15:25 ET Share this article Share to X Share this article Share to X LOS ANGELES , April 3, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Lakeland Industries, Inc. ("Lakeland" or the "Company") (NASDAQ: LAKE ) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LAKELAND INDUSTRIES, INC. (LAKE), CLICK HERE BEFORE APRIL 24, 2026 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. What Is The Lawsuit About? The complaint filed alleges that, between December 1, 2023 and December 9, 2025, Defendants failed to disclose to investors that: (1) Lakeland was experiencing significant, sustained issues with its Pacific Helmets and Jolly businesses, including, inter alia , shipping-related delays, production issues, and slower than expected rollout of new products; (2) accordingly, Defendants overstated the anticipated and actual positive impact of these businesses on Lakeland's financial results, as well as the overall strength and quality of Pacific Helmets' and Jolly's respective operations; (3) Lakeland's business and financial results were significantly deteriorating because of, inter alia , tariff-related headwinds and timing, certification delays, and material flow issues in its acquired businesses; (4) accordingly, Defendants overstated the strength of their tariff mitigation measures and "small, strategic, and quick" mergers and acquisitions strategy; (5) as a result of all the foregoing issues, Defendants' financial guidance was unreliable; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. The Law Offices of Frank R. Cruz, Email us at: [email protected] Call us at: 310-914-5007 Visit our website at: www.frankcruzlaw.com us for updates on Twitter: twitter.com/FRC_LAW . If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. SOURCE The Law Offices of Frank R. Cruz, Los Angeles 21 % more press release views with  Request a Demo × Modal title

Super Micro Computer, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SMCI News provided by DJS Law Group LLP Apr 03, 2026, 01:09 ET Share this article Share to X Share this article Share to X LOS ANGELES , April 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Super Micro Computer, Inc. ("Super Micro" or "the Company") (NASDAQ: SMCI ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: April 30, 2024 to March 19, 2026 DEADLINE: May 26, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. A significant amount of Super Micro's server sales were actually to China, in violation of U.S. export control laws. The Company's controls over export compliance were insufficient. Based on these facts, Super Micro's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email: [email protected] SOURCE DJS Law Group LLP 21 % more press release views with  Request a Demo × Modal title

IT Investors Have Opportunity to Lead Gartner, Inc. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Apr 04, 2026, 01:55 ET Share this article Share to X Share this article Share to X NEW YORK , April 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Gartner, Inc. (NYSE: IT ) between February 4, 2025 and February 2, 2026, both dates inclusive (the "Class Period"), of the important May 18, 2026 lead plaintiff deadline. So What: If you purchased Gartner common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do Next: To join the Gartner class action, go to https://rosenlegal.com/submit-form/?case_id=56538 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 18, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the Case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose facts concerning the true state of Gartner's growth rates; notably, that it was not truly equipped to handle ongoing challenges in its industry to either meet consulting revenue targets or to increase or even maintain its contract value ("CV") growth rate; Gartner's repeated claims of being able to achieve 12-16% CV growth rates in a "normal" macroeconomic environment proved to be unrealistic. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Gartner class action, go to https://rosenlegal.com/submit-form/?case_id=56538 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40 th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX News provided by DJS Law Group LLP Apr 03, 2026, 01:48 ET Share this article Share to X Share this article Share to X LOS ANGELES , April 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IBRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: January 19, 2026 to March 24, 2026 DEADLINE: May 26, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. ImmunityBio materially misstated the capabilities of its Anktiva medication. Based on these facts, ImmunityBio's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email: [email protected] SOURCE DJS Law Group LLP 21 % more press release views with  Request a Demo × Modal title

Trip.com Group Limited Securities Fraud Class Action Result of Antitrust Probe and 19% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC News provided by Kahn Swick & Foti, LLC Apr 10, 2026, 22:00 ET Share this article Share to X Share this article Share to X NEW YORK and NEW ORLEANS , April 10, 2026 /PRNewswire/ -- What's Happening: Continue Reading Kahn Swick & Foti Speed Speed --> Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 11, 2026 to file lead plaintiff applications in a securities class action lawsuit against Trip.com Group Limited (NasdaqGS: TCOM) ("Trip.com" or the "Company"), if they purchased or otherwise acquired the Company's securities between April 30, 2024 and January 13, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Eastern District of New York. What You May Do: If you purchased securities of Trip.com and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( [email protected] ), or visit https://www.ksfcounsel.com/cases/nasdaqgs-tcom/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 11, 2026 . About the Lawsuit: Trip.com and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On January 14, 2026, Bloomberg reported that the Company was the subject of an Antitrust Probe by the State Administration for Market Regulations of the People's Republic of China (the 'SAMR') based on allegations of "abusing its market position and engaging in monopolistic practices." The report further stated that, "[i]n September, the market regulator in Zhengzhou summoned Trip.com for violations of rules against setting "unfair restrictions" on merchants' transactions and prices." On this news, the price of Trip.com ADSs fell $12.90 per ADS, or 17.05%, to close at $62.78 per ADS on January 14, 2026. The next day, it fell a further $1.48 per ADS, or 2.35%, to close at $61.30 on January 15, 2026. The case is De Wilde v. Trip.com Group Limited, et al., Case No. 26-cv-01420. About Kahn Swick & Foti , LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit www.ksfcounsel.com . Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn SOURCE Kahn Swick & Foti, LLC 21 % more press release views with  Request a Demo × Modal title

Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit News provided by Law Offices of Howard G. Smith Apr 03, 2026, 15:24 ET Share this article Share to X Share this article Share to X BENSALEM, Pa. , April 3, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA ). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ATARA BIOTHERAPEUTICS, INC. (ATRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MAY 22, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected] , by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com . What Is The Lawsuit About? The complaint filed alleges that, between May 20, 2024 and January 9, 2026, Defendants failed to disclose to investors that: (1) certain manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (2) accordingly, tabelecleucel's regulatory prospects were overstated; (3) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical trials; (4) all the foregoing was likely to have a significant negative impact on Atara's business and financial condition; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact: Howard G. Smith, Esq., Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Call us at: (215) 638-4847 Email us at: [email protected] , Visit our website at: www.howardsmithlaw.com . To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact Us: Law Offices of Howard G. Smith Howard G. Smith, Esquire 215-638-4847 [email protected] www.howardsmithlaw.com SOURCE Law Offices of Howard G. Smith 21 % more press release views with  Request a Demo × Modal title

BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Mar 31, 2026, 15:22 ET Share this article Share to X Share this article Share to X NEW YORK , March 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Boston Scientific Corporation (NYSE: BSX ) between July 23, 2025 and February 3, 2026, inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. So what: If you purchased Boston Scientific common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Boston Scientific class action, go to https://rosenlegal.com/submit-form/?case_id=55398 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 4, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, during the Class Period, defendants made positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Boston Scientific's U.S. Electrophysiology segment; notably, that management was aware that the segment's growth rate was unsustainable and that it was approaching an earlier tipping point than the market was anticipating. Due to defendants' statements of confidence and lofty expectations, investors and analysts were left surprised by Boston Scientific's net income miss and underwhelming guidance for the first half of fiscal 2026. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Boston Scientific class action, go to https://rosenlegal.com/submit-form/?case_id=55398 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

Hercules Capital (HTGC) Under Fire: Class Action Filed After Allegations of Copying Google Ventures, Misstated Marks, and PIK Loans -- Hagens Berman News provided by Hagens Berman Sobol Shapiro LLP Apr 03, 2026, 22:12 ET Share this article Share to X Share this article Share to X SAN FRANCISCO , April 3, 2026 /PRNewswire/ -- Hercules Capital (NYSE: HTGC ) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired Hercules securities between May 1, 2025 and February 27, 2026. The lawsuit follows Hunterbrook Media's critical report, "The Myth of Hercules Capital," which in part claims that Hercules' sourcing process for deals merely copies those published on Google Ventures' website. The developments have prompted national shareholders rights firm Hagens Berman to investigate claims that Hercules violated the federal securities laws. The firm urges investors in Hercules who suffered significant losses to submit your losses now . The firm also encourages witnesses who may be able to assist in the investigation to contact its attorneys. Class Period: May 1, 2025 – Feb. 27, 2026 Lead Plaintiff Deadline: May 19, 2026 Visit: www.hbsslaw.com/investor- fraud /htgc Contact the Firm Now: [email protected] 844-916-0895 Hercules Capital, Inc. (HTGC) Securities Class Action: Hercules is a business development company that focuses on providing financing solutions (loans) to high-growth venture capital-backed and institutional-backed companies in a variety of technology and life sciences industries. The lawsuit is focused on the propriety of Hercules' disclosures about its investment origination and underwriting processes. In the past, Hercules has assured investors about the robust origination process for sourcing potential investments and the effectiveness of its due diligence process prior to underwriting its investments. The complaint alleges that Hercules overstated the due diligence with which it conducted its deal sourcing and loan origination process, overstated the due diligence with which it conducted its portfolio valuation process, and reported misclassified portfolio investments. As a result, the lawsuit claims, Hercules overstated or misrepresented its portfolio valuations and its net asset value ("NAV"). The company's assurances were brought into question on February 27, 2026, when Hunterbrook published its findings. In contrast to Hercules' assurances, Hunterbrook claimed in part that "according to a former Hercules analyst who worked on deal sourcing" the company's deal sourcing process essentially amounted to "'[g]o[ing] on the website for Google Ventures and just see what they invest in and just copy it.'" Hunterbrook also observed that Hercules is among the most software-exposed BDCs ("[a]bout 35% of the value of the company's loan portfolio") and "[d]espite billions worth of such debt across the industry falling into distressed territory […] Hercules still marks its software book at 100 cents on the dollar." Further, according to Hunterbrook's analysis, a growing share of Hercules' income is "phantom" because of the company's increasing usage of payment-in-kind ("PIK") loans to enable its borrowers to pay interest by adding to the principal of their debt rather than paying interest on their debt. Hunterbrook also spoke with a former member of Hercules' finance team who reportedly provided information that Hunterbrook said raised flags about the company's valuation process because, unlike other BDCs, the team was small and overstretched with few checks in place. This news drove the price of Hercules shares down nearly 8% on February 27, 2026. "We're investigating Hunterbrook's allegations and, if true, whether Hercules misled investors about its sourcing, underwriting, marks, PIKs, and, ultimately its NAV," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation. If you invested in Hercules and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now » If you'd like more information and answers to frequently asked questions about the Hercules case and the firm's investigation, read more » Whistleblowers: Persons with non-public information regarding Hercules should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected] . About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com . the firm for updates and news at @ClassActionLaw . SOURCE Hagens Berman Sobol Shapiro LLP 21 % more press release views with  Request a Demo × Modal title

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC News provided by Kahn Swick & Foti, LLC Apr 10, 2026, 22:00 ET Share this article Share to X Share this article Share to X Who is Involved : ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased between January 19, 2026 and March 24, 2025 When to Act: Deadline to file Lead Plaintiff applications is May 26, 2026 Basis: ImmunityBio shares fell on FDA warning letter over cancer therapy claims in advertisement NEW YORK and NEW ORLEANS , April 10, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio , Inc. (NasdaqGS: IBRX) ("ImmunityBio" or the "Company"), if they purchased or otherwise acquired the Company's securities between January 19, 2026 and March 24, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Central District of California. Continue Reading Kahn Swick & Foti Speed Speed --> What You May Do If you purchased securities of ImmunityBio and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( [email protected] ), or visit https://ksfcounsel.com/cases/nasdaqgs-ibrx-2/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 26, 2026 . About the Lawsuit ImmunityBio and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On March 24, 2026, a warning letter dated March 13, 2026, from the U.S. Food and Drug Administration to CEO Richard Adcock was made public, stating that a television advertisement and podcast misrepresented Anktiva and resulted in its distribution violating the Federal Food, Drug, and Cosmetic Act. The letter also reportedly noted that the violations "are concerning from a public health perspective because the promotional communications create a misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer." On this news, the price of ImmunityBio's shares fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026. The case is Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261. About Kahn Swick & Foti , LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit www.ksfcounsel.com . Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn SOURCE Kahn Swick & Foti, LLC 21 % more press release views with  Request a Demo × Modal title

RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Apr 04, 2026, 16:00 ET Share this article Share to X Share this article Share to X NEW YORK , April 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE ) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. So what: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Ultragenyx class action, go to https://rosenlegal.com/submit-form/?case_id=52472 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants provided investors with material information concerning Ultragenyx's expected results for its Phase III Orbit and Cosmic Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to demonstrate such ability and reduce testing variability that could interfere with such a result. The lawsuit claims that defendants provided these overwhelmingly positive statements to investors while simultaneously disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of setrusumab's potential, as well as the true risk inherent in the study protocols put forth; notably, that while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates or otherwise, that the Phase III Orbit and Cosmic studies were much less likely to be able to demonstrate such a link than management claimed. The lawsuit claims that such statements absent these material facts caused Ultragenyx shareholders to purchase Ultragenyx securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Ultragenyx class action, go to https://rosenlegal.com/submit-form/?case_id=52472 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

Navan, Inc. Notice of April 24, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline News provided by Kahn Swick & Foti, LLC Apr 10, 2026, 22:00 ET Share this article Share to X Share this article Share to X NEW YORK and NEW ORLEANS , April 10, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Navan, Inc. ("Navan" or the "Company") (NasdaqGS: NAVN) of a class action securities lawsuit. Continue Reading Kahn Swick & Foti Speed Speed --> CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Navan who were adversely affected if they purchased the Company's shares pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the "Offering Documents") issued in connection with Navan's October 2025 initial public offering (the "IPO"). the link below to get more information and be contacted by a member of our team: https://www.ksfcounsel.com/cases/nasdaqgs-navn/ Navan investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( [email protected] ), or visit https://www.ksfcounsel.com/cases/nasdaqgs-navn/ to learn more. CASE DETAILS: According to the Complaint, Navan and certain of its executives are charged with failing to disclose material information in the Offering Documents, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that the Company had increased its "sales and marketing" expenses for the quarter ending October 31, 2025 to nearly $95 million, or by 39% compared to $68.5 million sales and marketing expenses in the quarter ending July 31, 2025. When the true details entered the market, the lawsuit claims that the Company's shares fell sharply. The case is McCown v. Navan, Inc., Case No. 26-cv-01550. WHAT TO DO? If you invested in Navan and suffered a loss during the relevant time frame, you have until April 24, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff. About Kahn Swick & Foti , LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit www.ksfcounsel.com . Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn SOURCE Kahn Swick & Foti, LLC 21 % more press release views with  Request a Demo × Modal title

Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline News provided by Kahn Swick & Foti, LLC Apr 10, 2026, 22:00 ET Share this article Share to X Share this article Share to X NEW YORK and NEW ORLEANS , April 10, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics , Inc. ("Soleno" or the "Company") (NasdaqCM: SLNO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Soleno Therapeutics who were adversely affected by alleged securities fraud between March 26, 2025 and November 4, 2025. the link below to get more information and be contacted by a member of our team: Continue Reading Kahn Swick & Foti Speed Speed --> https://www.ksfcounsel.com/cases/nasdaqcm-slno/ Soleno investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( [email protected] ), or visit https://www.ksfcounsel.com/cases/nasdaqcm-slno/ to learn more. CASE DETAILS: According to the Complaint, Soleno and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) The Phase 3 clinical trial program for DCCR, the Company's only commercial product (for the treatment of hyperphagia in individuals afflicted with Prader-Willi syndrome or "PWS"), systematically minimized, mischaracterized, and/or failed to disclose substantial evidence of potential safety concerns associated with its administration, including indications of excessive fluid retention among clinical trial participants; (ii) as a result, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by the Company; and (iii) consequently, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout. The case is City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., No. 26-cv-01979. WHAT TO DO? If you invested in Soleno and suffered a loss during the relevant time frame, you have until May 5, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff. About Kahn Swick & Foti , LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit www.ksfcounsel.com . Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn SOURCE Kahn Swick & Foti, LLC 21 % more press release views with  Request a Demo × Modal title

Enphase Energy, Inc. Class Action Reminder - Robbins LLP Encourages ENPH Stockholders to Contact the Firm for Information About Their Rights News provided by Robbins LLP Apr 03, 2026, 15:22 ET Share this article Share to X Share this article Share to X SAN DIEGO , April 3, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Enphase Energy, Inc. (NASDAQ: ENPH ) securities between April 22, 2025 and October 28, 2025. Enphase is a global energy technology company focusing on solutions for solar generation, storage, and communication. Whas it the class period? April 22, 2025 – October 28, 2025 For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the allegations? Robbins LLP is Investigating Allegations that Enphase Energy, Inc. (ENPH) Misled Investors Regarding its Ability to Manage its Channel Inventory According to the complaint, during the class period defendants failed to disclose that: (i) Enphase overstated its ability to manage its channel inventory; (ii) Enphase overstated its ability to mitigate effects arising from the termination of the 25D Credit (which allowed homeowners to deduct 30% of costs of clean energy property they install at their homes) on December 31, 2025 instead of December 21, 2032; and (iii) accordingly, Enphase overstated its financial and operational prospects. Plaintiff alleges that on October 28, 2025, Enphase reported its financial results for the third quarter of 2025 and held a related earnings call. Among other items, Enphase's management reported that it expected 2025 to close on a weak note, with elevated channel inventory resulting in lower battery storage shipments in the fourth quarter, and that the expiration of the 25D Credit would negatively impact revenues for the first quarter of 2026. On this news, Enphase's stock price fell $5.56 per share, or 15.15%, to close at $31.14 per share on October 29, 2025. What can shareholders do now? You may be eligible to participate in the class action against Enphase Energy, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by April 20, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Enphase Energy, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. SOURCE Robbins LLP 21 % more press release views with  Request a Demo × Modal title

COTY INVESTOR ALERT: Coty Inc. (COTY) Sued After Surprise Profit Decline, CEO Exit, and Withdrawn 2026 Guidance -- Hagens Berman News provided by Hagens Berman Sobol Shapiro LLP Apr 03, 2026, 22:14 ET Share this article Share to X Share this article Share to X SAN FRANCISCO , April 3, 2026 /PRNewswire/ -- Coty Inc. (NYSE: COTY ) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired Coty common stock between November 5, 2025 and February 4, 2026. The lawsuit follows Coty's February 5, 2026 Q2 2026 earnings report, depicting serious operational issues, and the abrupt departure of its CEO (Sue Y. Nabi). This news drove the price of Coty shares down over 8% that day. The developments have prompted national shareholders rights firm Hagens Berman to investigate claims that Coty violated the federal securities laws. The firm urges investors in Coty who suffered significant losses to submit your losses now . The firm also encourages witnesses who may be able to assist in the investigation to contact its attorneys. Class Period: Nov. 5, 2025 – Feb. 4, 2026 Lead Plaintiff Deadline: May 22, 2026 Visit: www.hbsslaw.com/investor- fraud /coty Contact the Firm Now: [email protected] 844-916-0895 Coty Inc. (COTY) Securities Class Action: Coty is one of the world's largest beauty companies, with brands across fragrance, color cosmetics, and skin and body care. The company operates through two segments – Prestige and Consumer Beauty. The lawsuit is focused on the propriety of Coty's disclosures about business trends within these segments. Specifically, on November 5, 2025, in connection with the company's Q1 2026 financial results, Coty assured investors that it expected improvement in sales trends over the course of fiscal 2026. Nabi specifically assured investors that "we remain laser focused on strengthening our profitability and balance sheet, with our fiscal year 2026 business trends steadily improving in line with our expectations." The company reaffirmed its FY 2026 adjusted EBITDA target of $1 billion. The complaint alleges that Coty made false and misleading statements while failing to disclose that the Consumer Beauty market was underperforming, margins were compressed by increased marketing investments, and Prestige fragrance growth was slowing. Investors began to learn the truth a few weeks after the Q1 report when, on December 12, 2025, Coty announced without explanation the departure of CEO Nabi, driving the price of Coty shares significantly lower. Then, on February 5, 2026, the company announced its Q2 2026 financial results, revealing that Consumer Beauty's operating income plummeted over 70% from the year earlier period. In addition, though less severe, Prestige's operating income fell over 18% from the year earlier period. Coty also withdrew its FY 2026 EBITDA and free cash flow guidance. Management said during the earnings call that day, "[f]or Q3, we expect like-for-like revenue trends to decline mid-single digits, driven primarily by bigger declines in Consumer Beauty[]" and revealed "we estimate that the headwinds from retailer destocking significantly reduced in the quarter, the promotional environment intensified as we moved through the holiday period and remains elevated, which is a headwind to net sales and, by extension gross margin." This news drove the price of Coty shares down over 8% that day. "We're investigating whether Coty may have intentionally misled investors about its segment business trends and, if so, whether the year-over-year softness might be related to earlier reported destocking issues. We're also looking at the circumstances surrounding Ms. Nabi's abrupt and unexplained departure. " said Reed Kathrein, the Hagens Berman partner leading the investigation. If you invested in Coty and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now » If you'd like more information and answers to frequently asked questions about the Coty case and the firm's investigation, read more » Whistleblowers: Persons with non-public information regarding Coty should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected] . About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com . the firm for updates and news at @ClassActionLaw . SOURCE Hagens Berman Sobol Shapiro LLP 21 % more press release views with  Request a Demo × Modal title

INVESTOR DEADLINE: Eos Energy Enterprises, Inc. (EOSE) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit News provided by Robbins Geller Rudman & Dowd LLP Apr 03, 2026, 23:00 ET Share this article Share to X Share this article Share to X SAN DIEGO , April 3, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Eos Energy Enterprises, Inc. (NASDAQ: EOSE ) securities between November 5, 2025 and February 26, 2026, inclusive (the "Class Period"), have until Tuesday, May 5, 2026 to seek appointment as lead plaintiff of the Eos Energy class action lawsuit. Captioned Yung v. Eos Energy Enterprises, Inc. , No. 26-cv-02372 (D.N.J.), the Eos Energy class action lawsuit charges Eos Energy as well as certain of Eos Energy's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Eos Energy class action lawsuit, please provide your information here: https://www.rgrdlaw.com/cases-eos-energy-enterprises-class-action-lawsuit-eose.html You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected] . CASE ALLEGATIONS : Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility‑scale commercial and industrial applications. The Eos Energy class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Eos Energy was unable to achieve the ramp in production and capacity utilization required to achieve its previously set guidance; (ii) Eos Energy's battery line downtime was running well above industry norms, the design intent of the line, and internal forecasts; (iii) Eos Energy was experiencing delays in the ability for its automated bipolar production to hit quality targets; and (iv) Eos Energy's inadequate systems and processes prevented it from ensuring reasonably accurate guidance and that its public disclosures were timely, accurate, and complete. The Eos Energy class action lawsuit further alleges that on February 26, 2026, Eos Energy announced fourth quarter and full year 2025 results, reporting, among other things, full year 2025 revenue of $114.2 million, falling far short of Eos Energy's previously issued guidance of $150 million to $160 million for fiscal year 2025 revenue. Eos Energy allegedly further reported a "[g]ross loss of $143.8 million," a "[n]et loss attributable to shareholders of $969.6 million," an "[a]djusted EBITDA loss of $219.1 million," and further disclosed that its "capacity milestone was reached 5 weeks later than initially planned." On this news, the price of Eos Energy stock fell more than 39%, according to the complaint. THE LEAD PLAINTIFF PROCESS : The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Eos Energy securities during the Class Period to seek appointment as lead plaintiff in the Eos Energy class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Eos Energy class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Eos Energy class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Eos Energy class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: https://www.rgrdlaw.com/services-litigation-securities- fraud .html Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected] SOURCE Robbins Geller Rudman & Dowd LLP 21 % more press release views with  Request a Demo × Modal title

TCOM UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Trip.com Group (TCOM) Investors of Securities Class Action Deadline on May 11, 2026 News provided by Faruqi & Faruqi, LLP Apr 10, 2026, 11:28 ET Share this article Share to X Share this article Share to X Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Trip.com To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Trip.com between April 30, 2024 and January 13, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . [You may also click here for additional information] NEW YORK , April 10, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Trip.com Group Limited ("Trip.com" or the "Company") (NASDAQ: TCOM ) and reminds investors of the May 11, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com . As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants recklessly understated the regulatory risk facing Trip.com as a result of its monopolistic business activities; and (2) as a result, Defendants' statements about Trip.com's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. On January 14, 2026, Investing.com published an article entitled "Trip.com stock falls after Chinese regulators launch antitrust probe." The article stated that Trip.com stock fell after "the Chinese travel service provider disclosed it is under investigation by China's market regulator for potential antitrust violations." On this news, Trip.com American Depositary Shares ("ADS") fell 17% on January 14, 2026. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Trip.com's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Trip.com Group class action, go to www.faruqilaw.com/TCOM or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . us for updates on LinkedIn , on X , or on Facebook . Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. SOURCE Faruqi & Faruqi, LLP As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Defendants recklessly understated the regulatory risk facing Trip.com as a result of its monopolistic business activities; and (2) as a result, Defendants' statements about Trip.com's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. On January 14, 2026, Investing.com published an article entitled "Trip.com stock falls after Chinese regulators launch antitrust probe." The article stated that Trip.com stock fell after "the Chinese travel service provider disclosed it is under investigation by China's market regulator for potential antitrust violations." On this news, Trip.com American Depositary Shares ("ADS") fell 17% on January 14, 2026. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Trip.com's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Trip.com Group class action, go to www.faruqilaw.com/TCOM or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . us for updates on LinkedIn , on X , or on Facebook . Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. SOURCE Faruqi & Faruqi, LLP --> 21 % more press release views with  Request a Demo × Modal title

Rosen Law Firm Encourages SYLA Technologies Co., Ltd. Investors to Inquire About Securities Class Action Investigation - SYT News provided by THE ROSEN LAW FIRM, P. A. Apr 04, 2026, 01:48 ET Share this article Share to X Share this article Share to X NEW YORK , April 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of SYLA Technologies Co., Ltd. (NASDAQ: SYT ) resulting from allegations that SYLA Technologies Co., Ltd. may have issued materially misleading business information to the investing public. So what: If you purchased SYLA Technologies securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=56798 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. What is this about: Rosen Law Firm is investigating potential civil securities claims. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

BlackRock TCP Capital Corp. (TCPC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit News provided by Glancy Prongay Wolke & Rotter LLP Apr 03, 2026, 15:22 ET Share this article Share to X Share this article Share to X LOS ANGELES , April 3, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against BlackRock TCP Capital Corp. ("BlackRock" or the "Company") (NASDAQ: TCPC ). IF YOU SUFFERED A LOSS ON YOUR BLACKROCK INVESTMENTS, CLICK HERE BEFORE APRIL 6, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About? The complaint filed alleges that, between November 6, 2024 and January 23, 2026, Defendants failed to disclose to investors: (1) the Company's investments were not being timely and/or appropriately valued; (2) the Company's efforts at portfolio restructuring were not effectively resolving challenged credits or improving the quality of the portfolio; (3) as a result, the Company's unrealized losses were understated; (4) as a result, the Company's NAV was overstated; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay Wolke & Rotter LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: [email protected] Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at www.glancylaw.com . us for updates on LinkedIn , Twitter , or Facebook . If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact Us: Glancy Prongay Wolke & Rotter LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 Charles Linehan Email: [email protected] Telephone: 310-201-9150 Toll-Free: 888-773-9224 Visit our website at: www.glancylaw.com . SOURCE Glancy Prongay Wolke & Rotter LLP 21 % more press release views with  Request a Demo × Modal title

DOOR Deadline: DOOR Investors Have Opportunity to Lead Masonite International Corporation Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Apr 04, 2026, 01:10 ET Share this article Share to X Share this article Share to X NEW YORK , April 4, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds sellers of common stock of Masonite International Corporation (NYSE: DOOR ) between June 5, 2023 and February 8, 2024, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline. So What: If you sold Masonite common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Masonite class action, go to https://rosenlegal.com/submit-form/?case_id=52802 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, throughout the Class Period, defendants made material omissions and misrepresentations concerning Owens Corning's offers to purchase all of Masonite's outstanding common stock at significant premiums to Masonite's stock price and Masonite's repurchases of millions of dollars' worth of its shares without disclosing material nonpublic information about Owens Corning's offers, which, if disclosed as required, would have indicated to investors that Masonite's stock was worth significantly more. To join the Masonite class action, go to https://rosenlegal.com/submit-form/?case_id=52802 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

PayPal Holdings, Inc. (PYPL) Investors: April 20, 2026, Deadline in Securities Fraud Class Action Lawsuit News provided by Kessler Topaz Meltzer & Check, LLP Apr 05, 2026, 18:15 ET Share this article Share to X Share this article Share to X Did you buy PYPL common stock between February 8, 2024, and February 2, 202 6? Affected PayPal Holdings, Inc. Investor Summary Who : PayPal Holdings, Inc. ( NASDAQ: PYPL ) What: Securities fraud class action lawsuits filed Class Period: February 8, 2024, through February 2, 2026 Deadline to Seek Lead Plaintiff Status: April 20, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's projected revenue outlook and anticipated growth. Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options at no cost to investor RADNOR, Pa. , April 5, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ), a nationally recognized securities litigation law firm, informs investors that securities fraud class action lawsuits have been filed against PayPal Holdings, Inc. (PayPal) ( NASDAQ: PYPL ) on behalf of those who purchased or acquired PayPal common stock between February 8, 2024, and February 2, 2026, inclusive. Investors have until April 20, 2026, to file for lead plaintiff status. CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS: If you purchased or acquired PayPal common stock and have lost money on your investment, you are encouraged to contact KTMC attorney Jonathan Naji , Esq. at: (484) 270-1453 [email protected] https://www.ktmc.com/pypl-paypal-holdings-inc-class-action-lawsuit?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=pypl&mktm=PR There is no cost or obligation to speak with an attorney. PAYPAL HOLDINGS, INC. CLASS ACTION LAWSUITS - COMPLAINTS ALLEGATION SUMMARY: The complaints allege that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about PayPal's business and operations. Specifically, Defendants created the false impression that they possessed reliable information pertaining to PayPal's projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations. In truth, PayPal's optimistic plan for growth through various initiatives to bolster PayPal's Branded Checkout offerings fell short of reality as the 2027 targets were not achievable under the tenure of PayPal's CEO and required both an unrealistically stable consumer landscape and strong execution with clear direction from PayPal and its management. Why did PayPal's Stock Drop? On February 3, 2026, PayPal announced a surprise leadership change replacing the company's CEO. The leadership change coincided with PayPal's fourth quarter and full year 2025 earnings report, wherein PayPal missed consensus estimates for both revenue and profit. On this news, PayPal's stock price fell $10.63, or 20.3%, to close at $41.70 per share on February 3, 2026. WHAT PYPL INVESTORS CAN DO NOW: File to be lead plaintiff by April 20, 2026. Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you. Retain counsel of choice or take no action. THE LEAD PLAINTIFF PROCESS FOR PAYPAL HOLDINGS, INC. INVESTORS : PayPal investors may, no later than April 20, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages PayPal investors to contact the firm for more information. ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC): Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities- fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com . The complaints in this matter were not filed by KTMC. CONTACT: Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP 21 % more press release views with  Request a Demo × Modal title

Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX News provided by DJS Law Group LLP Apr 03, 2026, 01:07 ET Share this article Share to X Share this article Share to X LOS ANGELES , April 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. ("Aldeyra" or "the Company") (NASDAQ: ALDX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ALDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: November 3, 2023 to March 16, 2026 DEADLINE: May 29, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Aldeyra's drug candidate, reproxalap generated inconsistent results in clinical trials. The Company's positive statements about its clinical trials were unreliable. Based on these facts, Aldeyra's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email: [email protected] SOURCE DJS Law Group LLP 21 % more press release views with  Request a Demo × Modal title

Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit News provided by Law Offices of Howard G. Smith Apr 03, 2026, 15:22 ET Share this article Share to X Share this article Share to X BENSALEM, Pa. , April 3, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO ). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SOLENO THERAPEUTICS, INC. (SLNO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MAY 5, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected] , by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com . What Is The Lawsuit About? The complaint filed alleges that, between March 26, 2025 and November 4, 2026, Defendants failed to disclose to investors that: (1) the Soleno Phase 3 clinical trial program for DCCR had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (2) as a result, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by Soleno or its executives; and (3) consequently, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact: Howard G. Smith, Esq., Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Call us at: (215) 638-4847 Email us at: [email protected] , Visit our website at: www.howardsmithlaw.com . To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact Us: Law Offices of Howard G. Smith Howard G. Smith, Esquire 215-638-4847 [email protected] www.howardsmithlaw.com SOURCE Law Offices of Howard G. Smith 21 % more press release views with  Request a Demo × Modal title

Gemini Space Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Gemini Space Station, Inc. - GEMI News provided by ClaimsFiler Apr 03, 2026, 22:01 ET Share this article Share to X Share this article Share to X NEW ORLEANS , April 3, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until May 18, 2026 to file lead plaintiff applications in a securities class action lawsuit against Gemini Space Station , Inc. ("Gemini" or the "Company") (NasdaqGS: GEMI), if they purchased or otherwise acquired Gemini Class A common stock pursuant and/or traceable to the Company's September 12, 2025 initial public offering ("IPO"), and/or Gemini securities between September 12, 2025 and February 17, 2026 (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York. Get Help Gemini investors should visit us at https://claimsfiler.com/cases/nasdaq-gemi/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit Gemini and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) the Company had overstated the viability of its core business as a crypto platform; (ii) the Company had overstated its commitment to and/or the viability of growing its business through expanding its international operations; (iii) accordingly, the Company's post-IPO financial and business prospects were overstated; (iv) all of the foregoing raised a non-speculative risk that the Company was poised for an expensive and disruptive restructuring; and (v) as a result, the Offering Documents and defendants' public statements throughout the class period were materially false and misleading at all relevant times. The case is Methvin v. Gemini Space Station, Inc., et al., No. 26-cv-02261. About ClaimsFiler ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations. To learn more about ClaimsFiler, visit www.claimsfiler.com . SOURCE ClaimsFiler 21 % more press release views with  Request a Demo × Modal title

Fortinet Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortinet Inc. - FTNT News provided by Kahn Swick & Foti, LLC Apr 03, 2026, 22:04 ET Share this article Share to X Share this article Share to X NEW YORK and NEW ORLEANS , April 3, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC ("KSF"), announces that KSF has commenced an investigation into Fortinet Inc. (the "Company") (NasdaqGS: FTNT). On August 6, 2025, the Company disclosed disappointing second-quarter 2025 financial results, including that it was already "approximately 40% to 50% of the way through the 2026 upgrade cycle at the end of the second quarter [of 2025] based on the remaining active units and service contracts," that excess [firewall] capacity by customers meant less demand for upgrades, and also issued weaker-than-expected revenue guidance for the upcoming third quarter, projecting revenue between $1.67 billion and $1.73 billion. Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing. KSF's investigation is focusing on whether Fortinet's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws. If you have information that would assist KSF in its investigation, or have been a long-term holder of Fortinet shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn ( [email protected] ), or visit https://www.ksfcounsel.com/cases/nasdaqgs-ftnt/ to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit www.ksfcounsel.com . Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 1100 Poydras St., Suite 960 New Orleans, LA 70163 CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn SOURCE Kahn Swick & Foti, LLC 21 % more press release views with  Request a Demo × Modal title

Huntington Bancshares Incorporated Declares Cash Dividend On Its Series I & Series L Preferred Stock News provided by Huntington Bancshares Incorporated Mar 30, 2026, 16:05 ET Share this article Share to X Share this article Share to X COLUMBUS, Ohio , March 30, 2026 /PRNewswire/ -- Huntington Bancshares Incorporated announced that the Board of Directors declared and set aside a quarterly cash dividend on the company's 5.70% Series I Non-Cumulative Perpetual Preferred Stock (Nasdaq: HBANM ) of $356.25 per share (equivalent to $0.35625 per depositary share) payable June 1, 2026, to shareholders of record on May 15, 2026. The Board of Directors also declared and set aside a quarterly cash dividend on the company's 5.50% Series L Non-Cumulative Perpetual Preferred Stock (Nasdaq: HBANZ ) of $343.75 per share (equivalent to $0.34375 per depositary share) payable May 20, 2026, to shareholders of record on April 30, 2026. About Huntington Huntington Bancshares Incorporated is a $279 billion asset regional bank holding company headquartered in Columbus, Ohio. Founded in 1866, The Huntington National Bank and its affiliates provide consumers, small and middle-market businesses, corporations, municipalities, and other organizations with a comprehensive suite of banking, payments, wealth management, and risk management products and services. Huntington operates nearly 1,400 branches in 21 states, with certain businesses operating in extended geographies. Visit Huntington.com for more information. SOURCE Huntington Bancshares Incorporated 21 % more press release views with  Request a Demo × Modal title

NAVN SHAREHOLDER NOTICE: Lawsuit Alleges Navan's (NAVN) IPO Materials Omitted to Surge in Sales & Marketing Expenses - Hagens Berman News provided by Hagens Berman Sobol Shapiro LLP Mar 30, 2026, 16:00 ET Share this article Share to X Share this article Share to X Firm Reminds Investors of April 24 Lead Plaintiff Deadline SAN FRANCISCO , March 30, 2026 /PRNewswire/ -- N ational shareholder rights law firm Hagens Berman notifies investors in Navan, Inc. (NASDAQ: NAVN ) that the deadline to move for Lead Plaintiff in the pending securities class action is April 24, 2026 . REPORT YOUR NAVN INVESTMENT LOSSES TO HBSS NOW The lawsuit, McCown v. Navan, Inc., et al. , No. 26-cv-01550 , filed in the U.S. District Court for the Northern District of California, seeks to recover losses for investors who purchased Navan common stock pursuant or traceable to the company's October 2025 Initial Public Offering (IPO) . Investors in Navan (NAVN) are encouraged to visit: www.hbsslaw.com/cases/navan "Our investigation focuses on whether the registration statement issued in connection with Navan's IPO accurately reflected the company's financial trajectory," said Reed Kathrein , the Hagens Berman partner leading the firm's investigation of the alleged claims in the pending suit. Summary of NAVN Class Action's Allegations: The Omitted Costs of Growth The filed complaint against Navan, its top executives, and its IPO underwriters alleges that the IPO Registration Statement and Prospectus were false and misleading and omitted to disclose material facts. The $95 Million Expense Spike: That at the time of the IPO, Navan had already increased its sales and marketing expenses to approximately $95 million for the quarter ending Oct. 31, 2025—a 39% increase over the prior quarter ($68.5 million). Unsustainable Metrics: That this surge in spending was necessary to sustain the revenue and Gross Booking Volume (GBV) growth touted in the IPO documents. CFO Abrupt Departure: On December 15, 2025, just six weeks post-IPO, Navan revealed the sudden departure of its CFO, Amy Butte. 63% Value Erosion: On the news of the expense spike and CFO exit, Navan's stock fell nearly 12% in a single day. Since the IPO price of $25.00 , shares have plummeted to as low as $9.16 , representing a 63% decline for IPO investors Critical Deadline: April 24, 2026 If you purchased Navan common stock in or traceable to the October 2025 IPO , you have until April 24, 2026 , to ask the Court to appoint you as Lead Plaintiff. Submit Your Navan (NAVN) Investment Losses to HBSS Now Contact: Reed Kathrein at 844-916-0895 or email [email protected] If you'd like more information and answers to additional frequently asked questions about the case and the firm's Navan investigation, read more » Whistleblowers: Persons with non-public information regarding Navan should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected] . About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com . the firm for updates and news at @ClassActionLaw . SOURCE Hagens Berman Sobol Shapiro LLP 21 % more press release views with  Request a Demo × Modal title

TCOM INVESTOR ALERT: Trip.com (TCOM) Facing Class Action After AI Pricing Controversy and Anti-Monopoly Probe Sends Shares Tumbling -- Hagens Berman News provided by Hagens Berman Sobol Shapiro LLP Apr 03, 2026, 22:05 ET Share this article Share to X Share this article Share to X SAN FRANCISCO , April 3, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against China's largest online travel agency, Trip.com Group (NASDAQ: TCOM ) , seeking to represent investors who purchased Trip.com securities between April 30, 2024 and January 13, 2026. The lawsuit follows the 17% decline in the price of Trip.com American Depositary Shares on January 14, 2026. The selloff, which wiped out billions of dollars of the company's market capitalization, was triggered by the company's announcement that it is the subject of an investigation by regulators in China pursuant to the Anti-Monopoly Law of the People's Republic of China. The development and severe market reaction have prompted national shareholders rights firm Hagens Berman to commence an investigation into whether Trip.com violated the federal securities laws, as alleged in the complaint. The firm urges investors in Trip.com American Depository Shares who suffered significant losses to submit your losses now . Class Period: Apr. 30, 2024 – Jan. 13, 2026 Lead Plaintiff Deadline: May 11, 2026 Visit: www.hbsslaw.com/investor- fraud /tcom Contact the Firm Now: [email protected] 844-916-0895 Trip.com Group Limited (TCOM) Securities Class Action: In the past, Trip.com repeatedly touted its AI price adjustment tool, calling its AI approach "a cornerstone of our long-term strategy" and assured investors that its disclosure controls and procedures were effective. The company's price adjustment tool automatically lowers hotel rates on its platform when detecting higher prices elsewhere. The complaint alleges that these and other assurances misled investors because Trip.com materially understated the regulatory risk the company faced for its monopolistic business conduct. Investors began to learn the truth by late November 2025, when the financial press reported that hotel merchants partnering with Trip.com reported losing pricing autonomy under the company's platform. In addition, regulators scrutinizing the company reportedly identified the price adjustment tool as enabling Trip.com to force participation in promotions, undercut competitors, and penalize non-compliant merchants with reduced visibility or delisting. Then, on January 14, 2026, Trip.com revealed it "received a notice of investigation from the State of Administration for Market Regulations of the People's Republic of China (the 'SAMR')[]" and "the SAMR has commenced an investigation involving the Company pursuant to the Anti-Monopoly Law of the People's Republic of China." The market reacted swiftly, sending the price of Trip.com American Depositary Shares down $12.90 (-17%), wiping out over $8 billion of market capitalization in a single day. After the Class Period, on February 26, 2026, Trip.com announced with no explanation that its co-founders abruptly resigned from the company's board, effective the day before. Then, on March 8, 2026, pandaily reported that "Trip.com will shut down its automated hotel AI price adjustment tool on March 10, aiming to curb price wars and restore pricing autonomy for hotel partners." In addition, the article said "[s]everal hotel partners claimed the system automatically scanned competitors' prices and forced price reductions on their own listings, a practice some describe as 'one-sided coercion.'" "We're investigating whether Trip.com may have misled investors about the true purpose of its AI pricing tool and the sustainability of its business model without it," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation. If you invested in Trip.com American Depository Shares and have substantial losses, or have knowledge that may assist the firm's investigation, SUBMIT YOUR TCOM ADS LOSSES NOW » If you'd like more information and answers to additional frequently asked questions about the Trip.com case and the firm's investigation, read more » Whistleblowers: Persons with non-public information regarding Trip.com should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected] . About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com . the firm for updates and news at @ClassActionLaw . SOURCE Hagens Berman Sobol Shapiro LLP 21 % more press release views with  Request a Demo × Modal title

Power Solutions International, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PSIX News provided by DJS Law Group LLP Apr 01, 2026, 03:07 ET Share this article Share to X Share this article Share to X LOS ANGELES , April 1, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Power Solutions International, Inc. ("Power Solutions" or "the Company") (NASDAQ: PSIX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of PSIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: May 8, 2025 to March 2, 2026 DEADLINE: May 19, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Power Solutions overstated its ability to win business within the data center market for its power system solutions. The Company understated the costs and risk of "inefficiencies" in upgrading its manufacturing capacity to meet demand.Based on these facts, Power Solutions' public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate . WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: David J. Schwartz DJS Law Group 274 White Plains Road, Suite 1 Eastchester, NY 10709 Phone: 914-206-9742 Email: [email protected] SOURCE DJS Law Group LLP 21 % more press release views with  Request a Demo × Modal title

The Hanover Insurance Group, Inc. to Issue First Quarter Financial Results on April 29 News provided by The Hanover Insurance Group, Inc. Mar 30, 2026, 16:05 ET Share this article Share to X Share this article Share to X WORCESTER, Mass. , March 30, 2026 /PRNewswire/ -- The Hanover Insurance Group, Inc. (NYSE: THG ) expects to issue its first quarter financial results after the market closes on Wednesday, April 29, 2026. The company expects to webcast a discussion of its results on Thursday, April 30, at 10:00 a.m. ET, through its website at hanover.com . About The Hanover The Hanover Insurance Group, Inc. is the holding company for several property and casualty insurance companies, which together constitute one of the largest insurance businesses in the United States. The company provides exceptional insurance solutions through a select group of independent agents and brokers. Together with its agent partners, The Hanover offers standard and specialized insurance protection for small and mid-sized businesses, as well as for homes, automobiles, and other personal items. For more information, please visit hanover.com . Contacts: Investors: Media: Oksana Lukasheva Emily P. Trevallion (508) 525-6081 (508) 855-3263 Email: [email protected] Email: [email protected] SOURCE The Hanover Insurance Group, Inc. 21 % more press release views with  Request a Demo × Modal title

REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights News provided by Robbins LLP Apr 03, 2026, 15:19 ET Share this article Share to X Share this article Share to X SAN DIEGO , April 3, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX ) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States. For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the Class Period? February 9, 2022 – January 27, 2026 What are the allegations? Robbins LLP is Investigating Allegations that REGENXBIO, Inc. (RGNX) Misled Investors Regarding the Viability of its Drug Candidate RGX-111 According to the complaint, defendants continually touted RGX-111 as one of its lead clinical-stage AAV therapeutic product candidate RGX-111 for the treatment of MPS I using its proprietary NAV AAVP vector. Further, defendants announced in 2018 that RGX-111 had been granted Fast Track designation by the FDA and repeatedly represented that the Phase I/II RGX-111 studies were reporting positive results consistently highlighting "positive interim safety, tolerability, and biomarker data." Plaintiff alleges that in truth, defendants were aware of the serious safety issues relating to the RGX-111 study including the potential for CNS neoplasm and in November 2023 abruptly decided to de-prioritize its second-most advanced clinical candidate, RGX-111, and seek "strategic alternatives" for the program. The complaint continues that on January 28, 2026, defendants announced that the FDA placed a clinical hold on its investigational gene therapy RGX-111 following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I. Further, the FDA also placed a clinical hold on RGX-121 citing "the similarities in products, study populations, and shared risk between the clinical studies." On this news, the price of REGENXBIO's common stock declined from a closing market price of $13.41 per share on January 28, 2026 to $11.01 per share on January 28, 2026, a decline of 17.8% in the span of just a single day. What can shareholders do now? You may be eligible to participate in the class action against REGENXBIO, Inc. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by April 14, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against REGENXBIO, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. SOURCE Robbins LLP 21 % more press release views with  Request a Demo × Modal title

Leading Parkinson's Organizations Urge Congress to Preserve Progress and Strengthen Parkinson's Research Funding at the National Institutes of Health News provided by The Michael J. Fox Foundation for Parkinson's Research Apr 03, 2026, 15:41 ET Share this article Share to X Share this article Share to X NEW YORK , April 3, 2026 /PRNewswire/ -- As Congress reviews the President's federal budget proposal for Fiscal Year (FY) 2027, the three leading national Parkinson's advocacy organizations — on behalf of the 1.2 million Americans living with Parkinson's and related conditions — urge lawmakers to increase investment in the National Institutes of Health (NIH). The NIH is the primary driver of biomedical research progress, for the benefit of the health of Americans. This budget request, which includes a $5 billion reduction in funding for the NIH, would slow scientific breakthroughs that are needed now for millions of Americans living with disease. The American Parkinson Disease Association, The Michael J. Fox Foundation for Parkinson's Research and The Parkinson's Foundation collectively ask Congress to take action to increase federal funding for Parkinson's research to $600 million annually at the NIH. This level of funding represents less than 1% of the annual economic burden of Parkinson's, including spending by patients, families and the federal government, which totals $82.2 billion according to a recent report commissioned and supported by our organizations. Congress's bipartisan support for a strong NIH budget in FY 2026 reflected a shared commitment to scientific discovery, and it is critical that this momentum continue without delay. Additionally, a recent national survey shows that three in four voters favor doubling federal investment in Parkinson's research. Decades of NIH-supported research have led to the development of new treatments for Parkinson's disease and brought scientists closer than ever to meaningful breakthroughs in pursuit of a cure. Federal investment has also accelerated discoveries that reveal important connections across neurodegenerative diseases, opening new pathways for coordinated scientific advances with the potential to benefit millions. This is a pivotal moment to build on that progress. Last month, in Washington, D.C., our organizations convened more than 300 Parkinson's advocates from 49 states to share their experiences and call on their Members of Congress to increase federal investment in Parkinson's research at NIH. Their stories are a powerful reminder of the urgency of research funding to accelerate better treatments and cures for disease, and together, we stand ready to support efforts to strengthen NIH through the appropriations process. With this courageous nationwide community, millions strong, we call on Congress to ensure that a robust NIH remains central to the nation's investment in health and science — today and in the years ahead. About the American Parkinson Disease Association: The American Parkinson Disease Association (APDA) is a nonprofit organization dedicated to fighting Parkinson's disease (PD) by providing the support, education, research, and community that helps everyone impacted by PD live life to the fullest. Through a nationwide grassroots network of Chapters and Information & Referral (I&R) Centers, APDA works tirelessly to raise public awareness of this chronic neurologic movement disorder and deliver outstanding patient services, resources, and educational and wellness programs to the approximately one million people living with PD in the United States and their care partners and families. Envisioning a world without PD, APDA's national research program and Centers for Advanced Research aim to provide better treatments and unlock the mysteries of the disease. APDA is also committed to advancing public policy solutions that improve lives and move us toward a cure. Founded in 1961, APDA has raised and invested more than $338 million in its efforts to support the PD community. Learn more at www.apdaparkinson.org . About The Michael J. Fox Foundation for Parkinson's Research (MJFF): As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding $2.5 billion in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; creates a robust open-access data set and biosample library to speed scientific breakthroughs and treatment with its landmark clinical study, PPMI; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us at www.michaeljfox.org , Facebook , Instagram and LinkedIn . About the Parkinson's Foundation: The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson's community. Since 1957, the Parkinson's Foundation has invested more than $513 million in Parkinson's research and clinical care. Connect with us on Parkinson.org, Facebook , X , Instagram or call 1-800-4PD-INFO (1-800-473-4636). SOURCE The Michael J. Fox Foundation for Parkinson's Research 21 % more press release views with  Request a Demo × Modal title

Ortho Sport & Spine Physicians Expands to 63 Locations Across 18 States, Strengthening National Orthopedic Care Network News provided by Ortho Sport & Spine Physicians (OSSP) Apr 03, 2026, 15:57 ET Share this article Share to X Share this article Share to X ATLANTA , April 3, 2026 /PRNewswire/ -- Ortho Sport & Spine Physicians (OSSP), a privately owned spine and orthopedic practice, has expanded its national footprint to 63 locations across 18 states, making it one of the largest independently owned orthopedic networks in the country. The practice, founded in 2013 by Dr. Armin Oskouei, has opened more than 20 new locations in the past 24 months. With over 100 spine and orthopedic specialists on staff and more than 60,000 patient visits annually, OSSP continues to expand access to comprehensive musculoskeletal care nationwide. Continue Reading Ortho Sport & Spine Physicians / Unsplash.com "Our goal from the beginning was to build a national spine and orthopedic brand that never loses sight of the individual patient," said Dr. Armin Oskouei, founder of Ortho Sport & Spine Physicians. "Every new location we open is an opportunity to bring patient-centered care to a community that needs it." Comprehensive Services Under One Roof The organization provides a full spectrum of orthopedic services designed to address the complete range of musculoskeletal conditions. These services include interventional spine treatments such as targeted injections, orthopedic spine surgeries utilizing minimally invasive techniques, and extremity orthopedic procedures for sports medicine patients requiring joint and ligament care. OSSP also operates more than 50 MRI machines across its network, enabling rapid diagnosis and coordinated care from initial imaging through complete recovery. This integrated approach reduces the delays often associated with external referrals and keeps patients within a single care system throughout their treatment journey. "We bring together orthopedic surgeons, spine specialists, rehabilitation professionals, and advanced diagnostic services within an integrated care model," Dr. Oskouei explained. "This allows us to manage everything from imaging and evaluation to surgery, therapy, and recovery without patients having to navigate between different providers." Patient-Centered Care Model A defining element of OSSP's approach is its commitment to lower patient-to-provider ratios. The organization intentionally schedules fewer patients per provider, allowing physicians more time for thorough evaluations and customized treatment plans. "We see each patient as an individual, not a number," Dr. Oskouei said. "Our lower patient-to-provider ratio allows our doctors to spend more time understanding each patient's goals and lifestyle, which leads to better outcomes." This philosophy extends to treatment planning. Rather than applying standardized protocols, OSSP physicians design customized treatment plans tailored to each patient's specific condition, activity level, and recovery goals. The organization's primary focus is helping patients return to their quality of life prior to injury. Sports Medicine and Diverse Patient Care The practice has built a strong reputation in sports medicine, with affiliations to professional sports teams and a track record of treating both active and retired professional athletes. OSSP serves athletes of all ages and skill levels, applying the same level of expertise whether treating a professional competitor or a recreational player. "OSSP has had affiliations with professional sports teams and serves athletes of all ages," noted Dr. Oskouei. "We still treat active and retired professional athletes on a regular basis from these affiliations and our reputation in the sports medicine space." Beyond athletics, the organization serves a diverse patient population including workers' compensation cases, acute injury patients, and general orthopedic needs. Commitment to Innovation Staying current with advances in orthopedic medicine is a priority for the organization. OSSP works continuously to remain at the forefront of spine and orthopedic procedures through ongoing research and physician expertise. "We are constantly exploring new options to provide our patients with the best outcomes possible," Dr. Oskouei stated. Looking Ahead Ortho Sport & Spine Physicians has set a goal of reaching 100 or more locations as it continues its national expansion. The organization remains privately owned, allowing leadership to maintain focus on the values and patient-centered approach that have driven its growth. The company culture emphasizes collaboration, clinical excellence, and compassion. Every team member, from physicians to support staff, works together to create a supportive environment where patients feel heard, respected, and confident in their treatment. "Innovation, compassion, and teamwork are essential to delivering the highest quality orthopedic and spine care," Dr. Oskouei concluded. For more information, visit Ortho Sport & Spine Physicians . About Ortho Sport & Spine Physicians Ortho Sport & Spine Physicians (OSSP) is a privately owned spine and orthopedic practice founded in 2013 by Dr. Armin Oskouei. Headquartered in Atlanta, Georgia, the organization operates 63 locations across 18 states with a team of over 100 spine and orthopedic specialists. OSSP provides a full range of musculoskeletal services, including interventional spine treatments, orthopedic surgery, sports medicine, and diagnostic imaging. The practice is committed to delivering patient-centered care through an integrated model that prioritizes individualized treatment plans and accessible, high-quality orthopedic services. For more information, visit https://orthosportandspine.com . Media Contact Country : United States Media Contact : Liza Bradshaw ompany : GGPMEDIA LLC Email : [email protected] Phone number : +1 949-272-8729 Website : www.ggp.media Photo - https://mma.prnewswire.com/media/2949908/Ortho_Sport_Spine_Physicians.jpg SOURCE Ortho Sport & Spine Physicians (OSSP) 21 % more press release views with  Request a Demo × Modal title

OFN Statement on the Fiscal Year 2027 President's Budget Request News provided by Opportunity Finance Network Apr 03, 2026, 16:01 ET Share this article Share to X Share this article Share to X OFN Urges Continued Bipartisan Support for the CDFI Fund Which Advances American Economic and Affordability Priorities WASHINGTON , April 3, 2026 /PRNewswire/ --  Opportunity Finance Network  (OFN) released the following statement today in response to the White House's Fiscal Year (FY) 2027 budget request, which proposes a $204 million cut to the CDFI Fund and the redirection of funding to rural initiatives. The budget request also recommends deep cuts to other federal programs at the Small Business Administration's Office of Entrepreneurial Development and the Department of Housing and Urban Development (HUD), including HOME Investment Partnerships and Community Development Block Grant. "There can be no 'America First' agenda without investing in communities first. CDFIs drive economic opportunity in communities across America—from rural towns to urban neighborhoods—delivering jobs, affordable housing, and small business growth with proven efficiency and accountability," said Harold Pettigrew, OFN President and CEO . "The President's budget proposal is deeply disappointing, and risks weakening HUD, the SBA, and CDFI Fund investment programs at a time when Americans need more access to affordable capital—not less. CDFIs represent one of the most high-impact, market-based tools for advancing the Administration's housing affordability and job creation agenda, leveraging private investment to expand access to capital and strengthening local economies in places traditional markets often overlook. We urge the Administration and Congress to work together to restore critical investments that support small businesses, expand housing supply, and strengthen communities across America." For more than 30 years, the CDFI Fund has supported critical investments in small businesses, affordable housing, and economic opportunity in communities across the United States. The CDFI Fund is a highly effective vehicle for advancing President Trump's economic agenda: CDFIs leverage an estimated $8 in private sector investment for every $1 in public funding. In 2023 alone , CDFI Program recipients financed 109,151 businesses and 45,255 affordable housing units. The New Markets Tax Credit program has projected 28,957 permanent jobs, 59,244 construction jobs, and 37,409 tenant-based jobs for FY 2021–2023 activities. Cutting the Fund threatens that economic growth and weakens Main Street, jeopardizing thousands of projects that create local jobs, build affordable housing, and drive opportunity in communities across the country that rely on CDFIs as their primary source of affordable capital. Congress has a strong track record of standing behind the CDFI Fund through budget negotiations. In February, Congress passed , and President Trump signed into law, a bipartisan FY 2026 spending package that provided $324 million for the CDFI Fund. This came despite a White House budget request that proposed cutting CDFI Fund grant programs by nearly 90 percent. OFN will continue to work with Congress to preserve the current federal funding level of $324 million for the CDFI Fund in FY 2027 and share the important role that CDFIs play in their districts. CDFIs and industry allies also play a vital role in demonstrating the importance of the CDFI Fund. Now is the time to contact your elected officials and share how CDFIs are making a difference in your communities. Take action today through the OFN Policy Action Center . About Opportunity Finance Network Opportunity Finance Network (OFN)  is the nation's leading network and intermediary focused on community development investment, managing more than $1 billion in total assets and a membership of more than 490 community development financial institutions (CDFIs) , which includes community development loan funds, credit unions, green banks, banks, minority depository institutions, and venture capital funds. Our network of CDFIs works to ensure communities left behind by mainstream finance have access to affordable, responsible financial products and services, with a deep focus on serving rural, urban, and Native communities across the United States. OFN is a trusted investment partner to the public, private, and philanthropic sectors – foundations, corporations, banks, government agencies, and others – and, for more than 40 years, has helped partners invest in communities to catalyze change and create economic opportunities for all. SOURCE Opportunity Finance Network 21 % more press release views with  Request a Demo × Modal title

KD INVESTOR ALERT: New Kyndryl (KD) Securities Class Action Complaint Expands Class Period to August 1, 2024- Hagens Berman News provided by Hagens Berman Sobol Shapiro LLP Mar 30, 2026, 15:55 ET Share this article Share to X Share this article Share to X Litigation Alleges Reported Free Cash Flow Metrics Concealed True Financial Condition Prior to 55% Stock Collapse SAN FRANCISCO , March 30, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is alerting investors to an expanded securities class action filed against Kyndryl Holdings, Inc. (NYSE: KD ) . The new litigation expands the potential class of affected investors and introduces new allegations regarding the company's free cash flow reporting. REPORT YOUR KD INVESTMENT LOSSES TO HBSS . The newly filed action, Westchester Putnam Counties Heavy & Highway Laborers Local 60 Benefit Funds v. Kyndryl Holdings, Inc., et al. (S.D.N.Y.) , seeks to represent all persons and entities who purchased or otherwise acquired Kyndryl securities between August 1, 2024, and February 6, 2026 , inclusive (the "Expanded Class Period"). Kyndryl (KD) investors are encouraged to visit our updated case page to review the expanded allegations: www.hbsslaw.com/cases/kd , or view our latest video summary of the allegations: youtu.be/yBLSIN6NeQ0 "The litigation alleges that Kyndryl's much-touted free cash flow—a key indicator of the company's growth—was a mirage built on undisclosed and unsustainable cash management practices," said Reed Kathrein , the Hagens Berman partner leading the firm's investigation of the alleged claims in the pending litigation. "We are investigating whether the company used these practices to mask its true financial health, leading to the massive 55% value destruction when the CFO and General Counsel abruptly departed and the SEC's investigation became public." Kyndryl Holdings, Inc. (KD) Securities Class Action: Expanded Allegations While the initial complaint focused primarily on the failure to timely file financial reports and deficient internal controls, the expanded complaint alleges that throughout the Class Period, Kyndryl and its executives failed to disclose: Manipulated Cash Flow Metrics: That Kyndryl's reported free cash flow was artificially inflated by undisclosed and unsustainable cash management practices, rather than genuine operational strength. The August 2025 First Reveal: The complaint notes that the truth began to emerge on August 4, 2025 , when Kyndryl missed revenue and cash flow estimates, causing a 21% stock drop. Despite this, management allegedly continued to reassure investors about the "durability" of its financial condition. SEC Investigation & Executive Exodus: On February 9, 2026 , before the market opened, Kyndryl disclosed a voluntary document request from the SEC's Enforcement Division regarding its cash management practices. Simultaneously, the company announced the immediate departure of its CFO and General Counsel. Total Market Fallout: Following the February 9 announcement, Kyndryl's stock plummeted 55% , falling from $23.49 to $10.59 per share. Lead Plaintiff Deadline: April 13, 2026 Despite the filing of the new expanded complaint, the April 13, 2026 , deadline for investors to move for Lead Plaintiff remains unchanged. Submit Your Kyndryl (KD) Expanded Class Period Losses to HBSS Contact: Reed Kathrein at 844-916-0895 or email [email protected] If you'd like more information and answers to additional frequently asked questions about the firm's Kyndryl investigation, read more » Whistleblowers: Persons with non-public information regarding Kyndryl should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected] . About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com . the firm for updates and news at @ClassActionLaw . SOURCE Hagens Berman Sobol Shapiro LLP 21 % more press release views with  Request a Demo × Modal title

PINS Investors Have Opportunity to Lead Pinterest, Inc. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Mar 31, 2026, 15:14 ET Share this article Share to X Share this article Share to X NEW YORK , March 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Pinterest, Inc. (NYSE: PINS ) between February 7, 2025 and February 12, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 29, 2026. So what: If you purchased Pinterest securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Pinterest class action, go to https://rosenlegal.com/submit-form/?case_id=57800 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 29, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Pinterest was experiencing and/or was likely to experience reduced revenues from its advertising partners; (2) Pinterest overstated its ability to manage the impact of U.S. tariffs on the macroeconomic environment in which Pinterest operated, including the foreseeable impact on its advertising partners; (3) the impact of the foregoing on Pinterest's advertising revenues was significant enough that Pinterest was facing and/or likely to face an imminent restructuring; and (4) as a result, defendants' public statements were materially false and misleading at all times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Pinterest class action, go to https://rosenlegal.com/submit-form/?case_id=57800 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. 21 % more press release views with  Request a Demo × Modal title

NetDragon's Chairman and Controlling Shareholder Intends to Increase Shareholding, Underscoring Confidence in the Company's Long-Term Development USA - English APAC - Traditional Chinese APAC - English News provided by NetDragon Websoft Holdings Limited Mar 31, 2026, 03:43 ET Share this article Share to X Share this article Share to X HONG KONG , March 31, 2026 /PRNewswire/ -- NetDragon Websoft Holdings Limited ("NetDragon" or "the Company"; Hong Kong Stock Code: 777), a global leader in building internet communities, is pleased to announce that Chairman of the board of directors and controlling shareholder of the Company, intends to increase his shareholding in the Company by acquiring shares through open market transactions within 12 months from 30 March 2026. At this pivotal stage as NetDragon advances toward becoming a global leader in AIGC creation, Chairman of the board of directors and controlling shareholder of the Company's decision to increase his shareholding reflects his confidence in the Company's new strategic direction and long-term investment value. Looking ahead, NetDragon will continue to focus on its "AI+" core strategy, further strengthen its business presence. and enhance operational efficiency. As the Company pursues sustainable growth, it remains committed to delivering long-term, stable returns to shareholders and creating shared value together with all shareholders. About NetDragon Websoft Holdings Limited NetDragon Websoft Holdings Limited (HKSE: 777) is a global leader in building internet communities, with a long track record of developing and scaling multiple internet and mobile platforms that impact hundreds of millions of users. Over the desktop and mobile internet eras, NetDragon previously established China's first online gaming portal, 17173.com, and China's most influential smartphone app store platform, 91 Wireless. Established in 1999, NetDragon is one of the most reputable and well-known online game developers in China with a history of successful game titles including Eudemons Online , Conquer Online , Heroes Evolved and Under Oath . In the past 10 years, NetDragon has also achieved success with its EdTech business both domestically and globally. Fully embracing the new AI era, NetDragon is driving its vision of "Infinite Growth" through a dual-focus strategy of "AI+Gaming" and "AI+Education". With its AI Content Factory empowering operations and working with partners to develop a global learning metaverse, NetDragon is committed to once again building a massive user community in the new AI era. NetDragon's overseas edtech business entity, currently a U.S.-listed subsidiary named Mynd.ai, is a global leader in interactive technology and its award-winning interactive displays and software can be found in more than 2 million learning and training spaces across 126 countries. For investor enquiries, please contact: NetDragon Websoft Holdings Limited Email: [email protected] SOURCE NetDragon Websoft Holdings Limited 21 % more press release views with  Request a Demo × Modal title

Foundation for a Drug-Free World Volunteers Reach Athletes and Communities Across Italy During 2026 Winter Olympics News provided by Foundation for a Drug-Free World Apr 03, 2026, 23:14 ET Share this article Share to X Share this article Share to X MILAN, Italy , April 3, 2026 /PRNewswire/ -- During the 2026 Winter Olympics and Paralympics in Milano and Cortina, more than 600 volunteers with the Foundation for a Drug-Free World traveled across Italy to educate athletes, tourists and residents about the harmful effects of drugs and provide materials aimed at prevention. Continue Reading A Drug-Free World volunteer gives Truth About Drugs booklets to a torchbearer during the 2026 Winter Olympics. Post this A Drug-Free World volunteer shares The Truth About Drugs booklets with a torchbearer during the 2026 Winter Olympics in Italy, turning a moment of celebration into an opportunity for drug education and prevention. As the Olympic spirit brought people together, volunteers reached athletes, visitors and local communities with information aimed at helping youth and adults understand the dangers of drug use and choose a drug-free life. At the Milano Olympic Village, volunteers presented Truth About Drugs educational materials to 143 athletes and staff members. Those introduced to the campaign represented 37 countries, including Italy, Brazil, Belgium, Sweden, New Zealand and the Czech Republic, and signed a pledge to stay drug-free. After receiving a Truth About Drugs booklet, a Belgian speed skater emphasized the importance of education in prevention efforts: "The most important part is knowledge and how bad it could be for your body. The most important part is just knowing what happens because I think it's still not fully known, especially for the kids." He added, "We should all be drug-free, especially in sports where it's definitely dangerous to take drugs." Beyond the Olympic Village, volunteers distributed more than two million Truth About Drugs booklets throughout Italy. The materials were also placed in more than 12,000 shops, making them available to customers as well as tourists and local residents. Volunteers reported strong public interest in the campaign. In Milano, one volunteer group was approached by a woman who asked for a display stand after learning about the materials. According to the volunteers, she said there were about 100 families in her apartment building and that she would distribute the booklets herself. In Brescia, a volunteer described similar enthusiasm from local businesses: "The owner said he had already received one booklet display recently but had run out because he himself was putting one in each customer's bag with their meat." Volunteers said they encountered comparable responses in many cities along their route. The Foundation for a Drug-Free World is a nongovernmental drug education and prevention organization. Through its international network of volunteers, millions of educational booklets and prevention materials have been distributed in more than 190 countries. Supported by the Church of Scientology , these materials are provided free of charge to individuals and groups seeking to address drug abuse through education and prevention. For more information, visit www.drugfreeworld.org . SOURCE Foundation for a Drug-Free World 21 % more press release views with  Request a Demo × Modal title